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While the consequences of nuclear DNA damage have been well studied in a 
number of cell types, the exact consequences of acute and targeted mitochondrial DNA 
damage is less well understood.  This dissertation focuses on the examination of the 
outcomes of DNA damage directed at neuronal mitochondrial DNA in the absence of 
nuclear DNA damage.  I have used a microfluidic chamber model that allows for the 
spatial and fluidic isolation of neuronal soma (containing the nucleus and mitochondria) 
from the axons (containing mitochondria).  I found that exposure of the DNA-damaging 
drug cisplatin selectively to the axons was capable of inducing mtDNA damage in the 
axonal mitochondria without nuclear damage,.  Exposure of neuronal axons and 
mitochondria to the DNA damaging drugs cisplatin, d4T, or camptothecin all resulted in 
the degeneration of the exposed axons.  As there are three well-recognized pathways 
which are known to regulate axon degeneration in neurons, I investigated their roles in 
cisplatin-induced axon degeneration.  First, I found that deficiency of the proteins Bax 
and Caspase was unable to save neuronal axons from degeneration.  Additionally, 
inhibition of caspase activity using a pan-caspase inhibitor also was unable to prevent 
axon degeneration.  These findings indicate that the axon degeneration induced by 
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cisplatin exposure is not mediated by the apoptosis degenerative pathway or the axon 
pruning pathway.  I found that deficiency of Sarm1, an essential component of the 
Wallerian axon degeneration pathway, was also unable to save against this 
degeneration.  However, addition of the antioxidant glutathione was capable of inhibiting 
cisplatin-induced axon degeneration.  Thus, we find that the axon degeneration induced 
by cisplatin damage to mtDNA does not appear to be mediated by any of the known 
pathways of axon degeneration.  I also found that cisplatin exposure to axonal 
mitochondria led to a number of deficits in mitochondrial function—including 
mitochondrial aggregation, loss of mitochondrial membrane potential, production of 
reactive oxygen species, and inhibition of mitochondrial trafficking.  These findings 
indicated that directed mtDNA damage, in the absences of nuclear DNA damage, is 
capable of inducing significant mitochondrial deficits and eventually inducing cellular 
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CHAPTER 1: INTRODUCTION 
 
1.1 The mitochondrion 
Mitochondria are highly conserved, double-membrane structured organelles 
found in almost all eukaryotic cells including all four kingdoms of Eukarya-Plantae, 
Protista, Animalia, and Fungi.  As mitochondria are known to be almost universally 
conserved across these life forms, and mitochondrial failure has catastrophic 
consequences for the majority of organisms, mitochondria are broadly recognized as 
being an essential component of eukaryotic survival and success.  Mitochondrial 
research over the last two centuries has provided significant insights into their origin and 
function.  These now widely-recognized organelles initially were described by their 
physical morphology in the mid 1800’s where they gained their name from combination 
of the Greek word for threads-“mitos” and the word for grain or granule-“chondros” (1).  
After their initial discovery, mitochondrial research focused primarily on examining their 
metabolic functions and contributions to cellular biology such as oxidative 
phosphorylation  and the citric acid cycle (1).  Since then, mitochondria have been 
recognized as serving a number of additional critical functions in cells including cell 
cycle control (2), organismal development (3), cellular differentiation (4, 5), and cell 
death (6, 7).    
Mitochondrial origins however, are believed to have occurred outside of 
eukaryotes.  The endosymbiotic theory of mitochondrial genesis hypothesizes that 
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mitochondria were originally prokaryotic cells capable of oxidative respiration which later 
became incorporated and internalized within a eukaryotic cell as an endosymbiote (8-
10).  This ancient event is believed to have allowed the host cell the ability to undergo 
oxidative respiration while propagating the newly internalized primordial mitochondrion.  
Because mitochondria contain a number of functional elements similar to as bacteria, 
including mechanisms for replication and transportation of proteins, this is generally 
thought to be the origin of mitochondria, although other hypotheses exist as well (10, 
11).   
 
Mitochondrial structure 
These double-membraned organelles are relatively small, ranging from 0.75 to 3 
μm in diameter, although the exact morphology and number contained within a single 
cell tends to vary significantly with cell type (1, 12).  One of the most physically 
distinguishing aspects of mitochondrial biology is that they contain two highly 
specialized phospholipid bilayer membranes (illustrated in Fig. 1.1).  The two 
membranes involved are commonly referred to as the inner mitochondrial membrane 
(IMM) and the outer mitochondrial membrane (OMM).  The OMM  forms a continuous 
and smooth surface that covers the entirety of the mitochondrion and tends to be 
somewhat permeable, containing specialized import channels for large polypeptides 
and permitting diffusion of uncharged proteins under 5,000 kDa (13).  As such, small 
proteins can penetrate through the OMM from the cytosol into the intermembrane space 
between the IMM and the OMM.  In contrast to the OMM, the IMM is highly 
impermeable and has a distinct, highly folded membrane surface which forms folds 
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known as cristae (1, 14).  The IMM maintains its impermeability through a number of 
mechanisms, including the absence of porins and the inclusion of specialized lipids (15).  
The impermeability of the IMM plays a significant role in affecting the ability of the 
mitochondrion to undergo oxidative phosphorylation.  This occurs by engagement of the 
electron transport chain (ETC) machinery, which exists on the IMM, by allowing the ETC 
to establish a charge gradient across the IMM in the form of hydrogen cations (16).  
Embedded between the IMM and the OMM is the transmembrane space which contains 
a variety of proteins, such as cytochrome c, which are essential for metabolisms and 
cell survival (1, 17, 18).  The space contained within the bounds of the IMM is known as 
the mitochondria matrix.  The mitochondrial matrix contains the mitochondrial genome, 
consisting of a circularized strand of double stranded DNA, as well as key enzymes and 
metabolites involved in the citric acid cycle, oxidative phosphorylation, and other 
metabolic pathways (19).   
 
Oxidative phosphorylation and mitochondria energy production 
Because over 90% of a cell’s ATP comes from the mitochondria, their 
contribution to cellular metabolism and energy production is hard to understate (20).  
Within the mitochondria, the majority of energy production comes from the oxidative 
phosphorylation metabolic pathway.  Briefly, oxidative phosphorylation imports pyruvate 
from cytosolic glycolysis and converts it into acetyl-CoA, via pyruvate dehydrogenase, 
to incorporate into the citric acid cycle.  The citric acid cycle takes place within the 
mitochondrial matrix and cyclically incorporates acetyl-CoA to produce succinate and  
nicotinamide adenine dinucleotide (NADH).  These precursors are then incorporated 
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into reduction-oxidation (Redox) reactions, using oxygen as an oxidizing agent, and 
mediated by the ETC to generate an electropotential gradient.  The ETC is comprised of 
five large protein subunits that are imbedded within the IMM.  These complexes are 
known as Complex I (NADH dehydrogenase), Complex II (succinate dehydrogenase), 
Complex III (cytochrome c reductase), Complex IV (cytochrome c oxidase), and 
Complex V (ATP synthase) (illustrated in Fig. 1.2) (16, 21).  The redox reactions 
occurring in the ETC passes high-energy electrons derived from NADH and succinate 
down the ETC from Complex I to Complex IV, which is utilized to actively establish a 
proton (H+) charge gradient across the IMM as the ETC pumps hydrogen ions from the 
mitochondrial matrix into the mitochondrial intermembrane space.  This charge gradient 
establishes the mitochondrial matrix as a highly electronegative region with a strong 
electrochemical gradient across the IMM.  Complex V, also known as ATP synthase, 
harnesses this electropotential gradient to generate ATP by coupling the lower energy 
adenosine diphosphate (ADP) to an inorganic phosphate ion (Pi), utilizing the proton 
gradient for this energetically-demanding step by importing hydrogen ions back into the 
mitochondrial matrix (22).  Thus, ATP synthase directly couples the redox reactions 
occurring within the ETC and the citric acid cycle to the generation of ATP.   
 
1.2  Mitochondrial DNA and its replication 
A brief overview of mitochondrial DNA 
Mitochondria contain their own fully separate genome that replicates and exists 
completely independently from nuclear DNA.  The mitochondrial genome is commonly 
referred to as mitochondrial DNA (mtDNA) and exists in humans as a 16.6 kilobase pair 
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(kbp) circularized double-stranded DNA genome (23).  In mice, the mtDNA is a 16.3 kbp 
genome (24).  The mtDNA encodes for 13 of the 90 essential protein components of the 
ETC , as well as encoding for all 22 of the mitochondria transfer RNAs (tRNAs), and 
small (12S, MTRNR1) and large (16S, MTRNR2) ribosomal RNAs (rRNAs) subunits 
(Fig. 1.3) (23, 25).  The 13 peptide coding elements specifically encode seven 
components of the ETC’s Complex I, one component of Complex III, three components 
of Complex IV, and two components of Complex V (26).  The total number of distinct 
proteins in the mitochondria has been shown to be over 1,500 (27, 28).  So while 13 of 
those proteins are encoded by the mtDNA, the remainder of the components of the ETC 
and oxidative phosphorylation remains encoded by the nucleus.  Indeed, while the 
genetic material contained on the mtDNA is key for effective mitochondrial function, the 
remaining proteins that are expressed and localized in the mitochondria are encoded by 
the nucleus.   
Unlike the nucleus, which contains two chromosome sets of genetic material, a 
single mitochondrion contains between 2 to 10 copies of mtDNA (25, 29, 30).  These 
mtDNA copies exist on the inner surface of the mitochondria matrix as nucleoids which 
are colocalized with a number of proteins involved in dynamic mitochondria processes 
such as transcription and replication, including mitochondrial transcription factor A 
(TFAM) (30-32).   Differing again from the nuclear DNA, where one copy of each 
chromosome is inherited from both a maternal and paternal source, mtDNA is derived 
soley from the maternal lineage (26, 33).  Paternal mtDNA has been observed to be 
selectively eliminated from sperm mitochondria as part of the spermatogenesis pathway 
by the mitochondrial nuclease activity (34-37).  A minor fraction of paternal sperm 
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mtDNA appears to persist through this process (~100 copies/sperm) but is believed to 
be marked via a  ubiquitination flag for destruction after fertilization, although this 
process has been observed to fail to occur in abnormal embryos (38-40).   
 
Mitochondrial DNA replication 
The replication of mtDNA is an essential process for the maintenance and 
survival of both the individual cell as well as on an organismal level.  Unlike genomic 
DNA, mtDNA is not replicated only once every cell cycle (41).  Instead, mtDNA is 
believed to be continuously replicated throughout the life of a cell, as mitochondria are 
known to divide and merge together as a normal biological process (known as 
mitochondrial fission and fusion, respectively) as well as to be eliminated (41-45).  
Importantly, mtDNA replicates in post-mitotic tissues (e.g. neurons, cardiomyocytes) as 
well as in dividing cells (46).  As mitochondria replicate and grow, it is critical for 
mitochondria to retain an appropriate and adequate mtDNA copy number with high 
fidelity of the replicated genomes.  Indeed, altered mtDNA copy numbers have been 
implicated in a number of diseases including cancer, neurodegeneration, and aging (47-
50).  
Mitochondria contain their own distinct set of DNA replication machinery which is 
known as the mitochondrial replisome.  This replication machinery is interestingly not 
encoded with the mtDNA, but is instead encoded by the nucleus (41).  Genetic defects 
in the nuclear DNA encoding these proteins has been implicated in a number of known 
human diseases (45, 51, 52).  The core components of the mitochondrial replisome are 
the mammalian mitochondrial DNA polymerase gamma (POLG), the mitochondrial DNA 
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helicase TWINKLE, mitochondrial single-stranded DNA binding protein (mtSSB), and 
DNA-directed RNA polymerase, mitochondrial (POLRMT) (53).  POLG is the only 
identified mitochondrial DNA polymerase and is actually a holoenzyme comprised of the 
POLGA catalytic subunit which provides 5’-3’ exonuclease activity and the POLGB (also 
known as P55) catalytic subunit containing DNA processivity activity.  TWINKLE 
appears to play a key role in opening the double stranded mtDNA to allow the 
unwinding of short double-stranded DNA fragments with a 5’-3’ directionality to allow 
entry of POLG.  POLRMT is believed to provide RNA priming activity for POLG to allow 
for replication and mtSSB is known to tightly bind to single-stranded DNA and is thought 
to stabilize it.  In addition to these key mediators of mtDNA replication, several other 
proteins are believed to be additionally important for successful long-term propagation 
of DNA which includes the mitochondrial transcription factor TFAM, the 
helicase/endonuclease hDNA2, and the helicase hPIF1 (45, 54).  While TFAM does not 
appear to be strictly required for the replication of mtDNA, the genetic depletion of 
TFAM leads to depletion of mtDNA copy numbers which suggests that it plays an 
important role in the maintenance of mtDNA (31, 55, 56). 
 
1.3 Mitochondrial DNA damage  
Damage to the mtDNA has been well studied and is known to occur in response 
to a variety of both endogenous and exogenous factors. (41, 57).  As mentioned 
previously, damage to the mitochondrial DNA can lead to number of negative outcomes 
and is associated with several diseases (26, 45).  Potential endogenous mtDNA 
damaging events include expected events such as mismatch repair, aberrant DNA 
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replication, hydrolytic decomposition, or exposure to oxidizing ROS generating from 
oxidative phosphorylation.  Potential exogenous sources of mtDNA damage include 
ultraviolet radiation, ionizing radiation, and genotoxic chemical compounds.     
 
Deletions 
Deletions in mtDNA are relatively frequent events that occur natively during 
mtDNA replication and propagation within somatic cell populations.  Depending on the 
exact deletion event, and to the exact region of mtDNA targetted, the outcome can vary 
from not significant to toxic.  A single deletion event within a single mtDNA copy in a cell 
will likely be tolerated without incident.  However, if significant propagation of the 
deletion-damaged mtDNA genome occurs it can lead to mitochondrial toxicity and the 
development of a disease state.  Somatic mtDNA deletion events can occur over the 
lifetime of an organism leading to the accumulation of mtDNA deletions. Indeed, in 
aging these accumulated mtDNA deletions have been implicated in aging-associated 
tissue degradation (e.g. neurodegeneration, muscle fiber loss) (58, 59).   Somatic 
mtDNA deletion events accumulated over the lifetime of an organism have also been 
implicated in cancers (60).  The formation of mtDNA deletions within the maternal 
germline has been implicated in diseases which occur during development.  Unlike 
somatic mtDNA deletion events, these deletions are widely propagated throughout the 
host and have been indicated in a number of degenerative diseases including 





During normal replication of mtDNA genomes or DNA repair activities, POLG has 
the potential to incorporate a mismatched nucleotide which leads to a mismatched 
base.  These events are thought to be infrequent, as POLG is a high-fidelity polymerase 
with an error frequency of ~1 error in every 500,000 bp (64).  If mtDNA mismatches do 
occur they can be repaired by the mismatch repair pathway, but if they fail to be 
accurately repaired then these mismatch sites can lead to mtDNA mutations. 
 
Oxidative damage 
As mitochondria are home to the oxidative phosphorylation and the ETC in the 
cell, and the mtDNA exists on the inner matrix surface of the IMM which also contains 
the ETC, it is expected that mtDNA is exposed to a non-trivial amount of oxidative 
damage (65).  Indeed, it has been known that mtDNA is more likely to incur oxidative 
damage than nuclear DNA as well as being slower to repair the oxidative damage once 
it occurs (66).  The ROS generated within cells is known to be able to induce small 
oxidative changes that deform nucleotides.  Damage can include the generation of an 
abasic site, oxidized sugar backbones, or oxidized deoxyribose rings (67).  The primary 
product of oxidative damage to pyrimidine bases is considered to be thymine glycol, 
while the primary product of oxidative damage to purine is likely 7,8-dihydro-8-oxo-2’-
deoxyguanosine (8-oxodG)(57).  Thymine gycol tends to be less mutagenic but can 
inhibit POLG processivity until repaired, while 8-oxodG possess a greater mutagenic 




Apurinic/apyrimidinic sites (AP sites), also known as abasic sites, are a form of 
mtDNA damage where the DNA has completely lost the purine or pyrimidine normally 
located within the DNA backbone.  The formation of AP sites is known to occur in 
response to spontaneous depurination by hydrolytic deamination of mtDNA bases.  The 
formation of AP sites is also a key step during DNA repair pathways (69).   
 
Strand breaks 
Strand breaks in mtDNA can occur as both single-stranded and double-stranded 
breaks.  These breaks can occur in response to both endogenous and exogenous 
stimuli.  Endogenous sources of mtDNA strand break damage include defective 
replication events or aberrant repair of mtDNA damage.  Known exogenous sources of 
mtDNA strand breaks include ultraviolet radiation, ionizing radiation, environmental 
toxins, and chemotherapeutic drugs (45).  Interestingly, the mitochondrial polymerase 
POLG is the only human polymerase which is able to effectively incorporate the 
nucleoside analog drugs used for antiretroviral therapy into the polymerase and the 
mtDNA (70).  The incorporation of these nucleoside analog drugs into the mitochondrial 
genome leads to the termination of strand synthesis via POLG.  Abortion of strand 
synthesis by POLG induced by nucleoside analogs leads to a significant single-strand 
break event that can later lead to a double-strand break (65).  Single-strand breaks 
alone within the mtDNA backbone are repairable events with the native mtDNA repair 
pathways.  The formation of a double-stranded break to the mtDNA is more challenging 




Alkylation and adducts 
The sources of alkylating damage to the mitochondrial DNA primarily comes from 
exogenous sources, although endogenous sources of alkylating damage have been 
identified (e.g. S-adenosylmethionine)(71, 72).  A number of genotoxic agents such as 
tobacco smoke, environmental toxins, and chemotherapeutic agents have been 
identified to bind and form adducts with mtDNA (45, 65).  Specifically, the platinum class 
of chemotherapeutic drugs, which contains cisplatin, is known to bind DNA and form a 
variety of adducts including single-base adducts as well as both inter- and intra-strand 
crosslinks, typically between guanine bases (73).  In the case of cisplatin the most 
prevalent damage induced is the intrastrand crosslink of 1,2-d(GpG), with others 
occurring at a significantly reduced frequency (65, 74).  Intrastrand crosslinking by bulky 
adducts such as cisplatin can have catastrophic consequences on the mtDNA.  As 
intrastrand crosslinking events prevent the mtDNA from opening and inhibit both 
transcriptional and translational machinery, this functionally renders a stretch of the 
mtDNA unusable.  In addition, any attempt by this machinery to process through the 
damaged site can lead to strand breakage of the mtDNA proximal to the site of damage 
(75).   
 
1.4 The repair of mitochondrial DNA  
Like the nucleus, mitochondria contain DNA repair pathways capable of 
addressing DNA damage that may occur the mtDNA.  These DNA pathways have a 
number of parallels to nuclear DNA repair pathways, but remain distinct. 
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Base excision repair 
Base excision repair (BER) is considered to be the primary pathway engaged for 
the repair of the bulk of mtDNA damage.  Indeed, BER is the best characterized mtDNA 
repair pathway and is engaged to repair the most common forms of oxidative damage, 
non-helical distorting lesions, AP sites, single-strand DNA breaks, and some types of 
alkylating damage (76).  As mtDNA does experience a higher rate of oxidative damage, 
it is interesting to note that mitochondrial BER is actually more proficient at repairing the 
most common type of oxidative DNA damage (8-oxy-dG) than in the nucleus (77).  
There are two subtypes of BER known to mediate repair, short patch BER (SP-BER) 
and long patch BER (LP-BER).  SP-BER is used to replace single bases and is the 
primary type of BER implicated in mitochondria, although the machinery required for LP-
BER has been reported to be found in the mitochondria (Fig. 1.4) (78, 79). 
Mitochondrial BER is mediated via a series of well-defined stepwise processes 
that lead to the successful repair of damaged mtDNA.  Specifically, these steps include 
the recognition of the damage site, excision of the damaged base to generate an AP 
site, DNA strand cleavage at the AP site, strand end processing, strand gap filling, and 
ligation of the repaired strand (57).  Base recognition and excision in mitochondrial BER 
occurs via DNA glycosylases, which cleave the N-glyosylic bond between the damaged 
base and the DNA backbone to form an AP site.  Mitochondria contains four bifunctional 
DNA glycosylases (OGG1, NTHL1, NEIL1, and NEIL2), which can recognize either 
damaged ssDNA or dsDNA, and two monofunctional DNA glyosylases (UNG1 and 
MUTYH), which only recognize dsDNA damage sites (76).  Mitochondrial APE1 then 
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processes the ends at the cleavage site, POLG fills in the gap, and then the ends are 
sealed and ligated by DNA Ligase IIIα. 
 
Nucleotide Excision Repair (NER) 
NER is a robust and distinct pathway for the repair of single-stranded DNA and is 
capable of repairing damage that induces significant conformational change to the DNA 
helix.  It has been largely implicated in the repair of large bulky adducts such as 
cisplatin-induce intrastrand-crosslinks, damage caused by intercalating agents, 
radiation-induced adducts, and those produced by environmental toxins.  These 
damage events, which are not readily repaired by the BER pathway, are repaired by 
NER-mediated DNA repair (80).  This pathway of DNA repair is utilized by the nucleus 
for maintenance and repair of nuclear DNA.  However, there is no evidence for the 
involvement of the NER repair pathway in mammalian mitochondria (81, 82).  Thus, 
certain types of DNA damage that normally require NER for repair in the nucleus (such 
as cisplatin intrastrand crosslinks) do not appear to be repairable within the 
mitochondria (45, 57, 80, 82-84).  Importantly, these damage types are therefore more 
likely to be capable of inducing more significant and long term consequences when they 
induce damage to mtDNA than to nuclear DNA. 
 
Mismatch repair 
Mismatch repair has been well reported as an important and conserved mediator 
of the removal and replacement of mismatched nucleotide incorporation into the nuclear 
genome.  In mammalian mitochondria however, this process has not been as clearly 
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implicated as an essential process for the maintenance of the mitochondrial genome 
(85).  One report has described the existence of a mismatch repair-like system in rat 
mitochondria, but this process does not appear to have a clear strand preference for 
repair of the mismatched base (86).  Additionally, this process did not appear to be 
dependent on the reported nuclear mismatch repair components (MSH family proteins, 
homologs of bacterial MutS) (86).  More recent research has indicated the repair factor 
YB-1 may be a mitochondrially relevant mediator of mismatch repair, but its exact 
contribution remains unclear (87). 
 
Double-strand break repair 
The repair of double-stranded breaks in the nucleus is primarily achieved through 
either homologous recombination or by nonhomologous end-joining (NHEJ).  There is 
evidence that yeast and plants are capable of repairing mtDNA double-strand breaks by 
homologous recombination pathways, however homologous recombination does not 
appear to occur in significantly detectable levels in mammalian mitochondria (88-91).  
Thus in mammalian mitochondria, homologous recombination is not a major pathway 
engaged in the repair of double-stranded DNA breaks.  NHEJ represents the other 
potential pathways for the repair of double-strand breaks in mtDNA.  Indeed, extracts of 
mitochondria have been found to be capable of joining together broken double-stranded 
DNA in vitro (92).  However, this process occurs at low frequencies and is not thought to 
be a major contributor to the repair of double-stranded breaks in mammalian mtDNA 
(57, 92).  Thus, mitochondria do not appear to be highly competent in the repair of 




Damaged or aberrant mitochondria can have negative consequences for a cell 
and an organism.  These damaged mitochondria are capable of producing damaging 
amounts of ROS, consuming cellular resources, and potentially inducing apoptosis.  As 
such, cells have developed a mechanism that permits the selective elimination of these 
damaged mitochondria known as mitophagy (93).  Mitophagy is a specialized form of 
cellular autophagy that leads to the flagging of damaged mitochondria to be degraded 
utilizing a subset of the components of the autophagy pathway.   
Damaged mitochondria are recognized by the mitophagy pathways by loss of the 
mitochondrial membrane potential across the IMM (93).  Deterioration of the ability to 
maintain a sufficient electrochemical membrane potential gradient across the IMM often 
results from a critical failure of the ETC and oxidative phosphorylation.  Failure of these 
pathways suggests that the mitochondrion is unfit to maintain its basic functions and 
should be eliminated before it can induce damage to the cell as a whole.  The loss of 
membrane potential is known to lead to the stabilization of interaction of the PINK1 
protein and the OMM (94-96).  In healthy mitochondria, PINK1 undergoes import 
through the OMM and is locally degraded within the transmembrane space, thus 
inhibiting a stable association with the OMM (94, 95).  Once stabilized, PINK1 
phosphorylates a number of OMM targets including S65 of OMM ubiquitin residues (97).  
The ubiquitin ligase Parkin is recruited from the cytosol to the OMM, as Parkin has a 
high affinity for this modification.  Once associated with the OMM of a depolarized 
mitchondria, Parkin undergoes a conformational shift and becomes capable of 
executing the addition of polyubiquitination chains to the OMM .  PINK1/Parkin activity 
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leads to the conjugation of a number of different types of polyubiquitin chains to the 
OMM (including K48-, K63-, K11-, and K6-linked chains) (98).  This polyubitination of 
the OMM leads to the initiation of the formation of an isolating double-membraned 
autophagosome around the flagged mitochondrion, which is mediated by a number of 
now well-defined autophagy-associated proteins (98, 99).  Once fully engulfed by the 
autophagosomal membrane, the mitochondrion undergoes complete degradation upon 
the fusion of the autophagosomal membrane with a lysosome (93). 
 
1.6 Mitochondrial ROS 
Mitochondria are a key source of ROS within mammalian cells.  Specifically, 
superoxide radical is the predominant form of ROS generated by the mitochondria 
(100).  Superoxide is generated in the mitochondria as a consequence of oxidative 
phosphorylation and the activity of the ETC, where Complex I and Complex III are major 
contributors (100).  The superoxide free radical is managed by the mitochondria by 
constitutively degrading it into less reactive forms, such as the conversion of superoxide 
into H2O2 by mitochondrial superoxide dismutase (SOD) (101).    H2O2 is later degraded 
and converted into water by the activity of glutathione peroxidase and peroxiredoxins 
(102).  The degradation of H2O2  is an important step, as if left unchecked it can lead to 
the generation of hydroxyl radicals though an interaction with Fe2+, known as the Fenton 
reaction (100, 102).  The hydroxyl free radical is highly reactive with almost all 
biomolecules and can lead to significant damage to cellular components (e.g. lipids, 
proteins, nucleic acids) (100, 102).  Superoxide and various other forms of ROS 
molecules are now thought to play a number of important roles in cellular signaling 
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pathways important for proper cellular homeostasis (103, 104).  Although ROS signaling 
is utilized for a number of cellular functions, mitochondria production of ROS leads to 
higher levels of localized ROS within the mitochondria.  Indeed, the mitochondrial matrix 
under basal conditions is known to contain between 5- to 10-time the relative amounts 
of superoxide found within the cytoplasm or nucleus (102).  Damage to the mtDNA is 
known to lead to dysfunction of oxidative respiration in mitochondria and the aberrant 
and excessive formation of damaging ROS species (105, 106).   
Glutathione (GSH) is a key endogenous antioxidant produced by the cell which 
helps mediate the consequences of ROS, including by reducing and eliminating various 
ROS species and free radical ions (107).  GSH functions as a key component of the 
conversion of H2O2 into water in association with glutathione peroxidase (102).  In 
addition to that role, GSH exists throughout both the cell and the mitochondria, 
providing a broad capability of combating ROS throughout the cell.  Upon interaction 
with an oxidizing agent, reduced cellular GSH is converted into an oxidized state and 
forms into glutathione disulfide (GSSG).  GSSG is then reduced back into reduced GSH 
by the activity of glutathione reductase (107, 108). 
   
1.7 Mitochondrial Dynamics 
Mitochondria exist in a wide variety of morphologies, dependent upon cell type.  
They exist in dynamic networks, that can range from highly divided and granular to 
largely fused long  threads winding within a cell.  They are dynamic and mobile 
organelles that do not statically exist in a single location within a cell but instead 
undergo active transport throughout the cell.   
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Mitochondrial fission and fusion 
Early reports of mitochondria described them under static imaging conditions, but 
upon study in live cells it was discovered that mitochondria are actually capable of 
undergoing division and fusion (109-111).  These division and fusion events of 
mitochondrial have become known as mitochondrial fission and fusion, respectively.  In 
recent years, there has been a growing appreciation for mitochondrial fission and fusion 
and their contributions towards mitochondrial stability, health, and responses towards 
cellular stress.  It has been proposed that the fusion of mitochondria may help mediate 
mitochondria stress response by the fusion of a damaged mitochondria with an 
undamaged one as a form of complementation to rescue and regenerate the damaged 
mitochondrion (44).  While fusion has been indicated to have roles in mitochondrial 
repair and maintenance, mitochondrial fission has been instead implicated in the birth 
and expansion of mitochondria.  As damaged mitochondria are eliminated or a cell 
divides, mitochondria replicate and undergo fission to expand and replenish the pool of 
healthy and functional mitochondria.  Together, mitochondrial fission and fusion has 
been proposed as a potential mechanism of mitochondrial quality control, cellular 
growth, responses to changes in cellular metabolism, cell survival and death, diseases, 
and a number of other key cellular roles (44, 110, 112, 113).   
These pathways have become reasonably well understood in mammals in recent 
years, as their mechanisms appear to be conserved between yeast, flies, and mammals 
(114).  Briefly, the major components of these pathways appear to be members of the 
dynamin family of large GTPase.  The mammalian protein Drp1 is the primary 
regulators of mitochondrial fission, although other Drp1 binding partners play a role (44, 
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114).  Fusion of mitochondrial instead require alternate dynamin family members, 
specifically the mitofusins (MFN1 and MFN2) and OPA1.  MFN1 and MFN2 are 
essential mediators of the fusion of the OMM of mitochondria.  Interestingly, MFN2-
mediated fusion events appear to involve the pro-apoptotic protein Bax (115).  Fusion of 
the IMM is instead mediated by OPA1 and not the mitofusins (114).   
 
Mitochondrial movement 
In addition to the dynamics provided by the ability to undergo fission and fusion, 
mitochondria are also highly mobile organelles.  Mitochondria are known to be actively 
trafficked along the microtubule-based cytoskeleton within a cell.  The ability to mobilize 
and transport mitochondria within the cell allows cells to localize mitochondria to 
discrete subcellular localizations where they may be required most.  One cell type 
where this is most notable is in neurons.  Neurons contain both a cell body and long 
axons, that can reach distances of up to one meter in humans (116).  As such, the 
ability to successfully transport mitochondria over long ranges is essential for the proper 
health and survival of an organism.  Mitochondria are trafficked through active 
transportation on microtubules and are powered by microtubule motor proteins-dynein 
and kinesins (117, 118).  Mitochondrial are complexed to these microtubule motor 
proteins by the mitochondrial cargo adaptor proteins, Miro and Milton (Fig. 1.5) (119, 
120).  Neurons rely upon these transportation pathways to ensure that all lengths of the 
neuronal axon are supplied with healthy mitochondria to enable full functionality of the 
cell across its length (120).  Interestingly, the transport of mitochondria appears to be 
integrated into the mitophagy-based checkpoint control system of mitochondrial 
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function.  If mitochondria become damaged and depolarized, they recruit PINK1/Parkin 
to them which leads to the interaction of PINK1/Parkin with the microtubule motor tether 
proteins leading to phosphorylation and subsequent ubiquitin-mediated degradation 
(120, 121).  The loss of Miro means that damaged and defective mitochondria stall out 
on microtubules and do not undergo trafficking until they are repaired or eliminated. 
 
1.8 Chemotherapy-induced peripheral neuropathy (CIPN) 
Chemotherapy-induced peripheral neuropathy (CIPN), a condition in which the 
peripheral nervous system is damaged by the treatment of chemotherapeutic drugs, can 
induce significant axon damage causing numerous neurological deficits in cancer 
patients (122-124).   These deficits can initially manifest in a number of ways, leading to 
symptoms in the hands and feet such as pain, numbness, tingling, as well as sensory 
loss.  These symptoms can progressively worsen throughout treatment, resulting in the 
development of significant sensory pain, motor ataxia, pain, extreme numbness and 
loss of sensation (125).  Those symptoms make CIPN often the dose-limiting factor in 
the dosage of chemotherapeutic drugs and reducing the maximum benefit available to 
patients (126).  Among the frontline drugs that are associated with severe CIPN are the 
platinum compounds such as cisplatin (122-124, 127, 128).  Incidentally, peripheral 
neuropathy is also observed in HIV patients that are prescribed anti-retroviral drugs 
such as d4T (129).  Importantly, while the antineoplastic mechanisms of these drugs are 
well-studied in proliferating cells (e.g. by targeting mitosis and DNA replication 
pathways), the fact that many of these drugs induce axon degeneration in postmitotic 
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neurons is mostly unexpected and the exact mechanisms involved remain largely 
unknown. 
The exact pathologies involved in CIPN may vary, but most seem to result in 
axonal damage which leads to the “dying back” of the axon (130).  The “dying back” 
phenotype is generally regarded as the degeneration of the distal tip of the axon back to 
the neuronal cell body.  Different chemotherapeutic agents are thought to induce CIPN 
through different mechanisms.  For example, chemotherapeutic drugs that disrupt 
microtubule stability (such as taxanes or vincristine) are known to induce CIPN in 
peripheral sensory and motor neurons, as these neurons rely upon properly working 
microtubule networks in their peripheral axons for maintenance of basic functions (131, 
132).  Other chemotherapeutic drugs, such as the platinum agents, including cisplatin 
and carboplatin, are DNA damaging agents and it is less clear what the mechanisms 
are which lead to CIPN in response to platinum therapies. 
 
Cisplatin-induced CIPN 
The platinum class of chemotherapeutic agents, including cisplatin, is known to 
induce their effects by damaging DNA by forming a platinum-DNA adduct.  Platinum 
drugs are known to be relatively severe inducers of CIPN in patients, with up to 90% of 
patients experiencing sensory neuropathies (133, 134).  The neuropathic damage 
induced by cisplatin is dose-dependent and can lead to long term neurological deficits 
(130). Cisplatin damages DNA primarily in the form of inter- and intra-strand crosslinks, 
typically between guanine bases (73).  Specifically, the primary form of DNA damage 
induced by cisplatin is the intrastrand crosslink of 1,2-d(GpG) (65, 74).  The CIPN 
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observed in response to cisplatin has been reported to be capable of inducing the dying 
back axon degeneration pathology prior to the full loss of the neuronal cell body (130).  
Some research has shown that in peripheral neurons cisplatin causes both damage to 
the nucleus as a well as the mitochondria (135-137).  However, the exact contribution of 
this damage and how it leads to the dying back phenotype of axon degeneration prior to 
neuronal degeneration remains unclear. 
 
1.9 The known pathways of axon degeneration 
Neuronal development and target innervation by axons and dendrites are 
essential processes required for the establishment of the nervous system.  
Simultaneously however, the selective destruction of neurons or only their projections is 
also important for the refinement of the wired brain (138).  Although, the mechanisms 
regulating the survival and elimination of neurons via apoptosis during development are 
well studied, the pathways governing the selective degeneration of the axons are less 
understood.  Axon degeneration is predominantly studied in three contexts: 1) Axotomy 
(also known as Wallerian degeneration) where the severing of axons results in the 
degeneration of axons distal to the cut site; 2) Apoptosis-induced axon degeneration, 
where the entire neuron is exposed to apoptotic stimuli (e.g. global deprivation of trophic 
factors) resulting in the degeneration of both axons and soma; and 3) Pruning-induced 
axon degeneration, which here is referred to here as “Axon Pruning”, where a subset of 
axons are selectively exposed to pruning stimuli (e.g. axon-only or “local” deprivation of 
trophic factors) which results in the selective degeneration of only the axons exposed to 




Wallerian degeneration is a unique and structured form of axon degeneration that 
occurs when a neuronal axon is crushed or severed (axotomized) from its cell body. 
Wallerian degeneration has been well examined in the Wlds mouse, where axotomy-
induced axon degeneration is strikingly inhibited (139).  Wlds mice express a unique 
gene product responsible for this protection which was identified as the fusion of the N-
terminal fragment of ubiquitination factor E4B (UBE4b) with NMNAT1 (nicotinamide 
mononucleotide adenyltransferase 1) (140).  These findings implicated the role of NAD+ 
(nicotinamide adenine dinucleotide) metabolism in Wallerian degeneration, as NMNATs 
are key ienzymes in the NAD+ salvage pathway.  NAM (Nicotinamide), which is a 
byproduct of NAD+ metabolism, is recycled into NMN (nicotinamide mononucleotide). 
NAD+ can then be regenerated from NMN by the NMNAT enzymes to maintain steady-
state pools of intracellular NAD+.  The rapid depletion of NAD+ has been identified to be 
a central event in axons undergoing Wallerian degeneration and addition of exogenous 
NAD+ (albeit at high concentrations) is sufficient to inhibit this degeneration (141-143).   
However, recent evidence suggest that rather than NAD+ depletion, it could be the 
accumulation of NMN instead that triggers axon degeneration (144).  
Recently, SARM1 (Sterile Alpha and TIR Motif 1) was identified as an essential 
mediator of the axotomy-induced axon degeneration (145, 146).  SARM1-deficiency 
robustly protects axons following axotomy in vivo and in vitro (145, 146) and maintains 
NAD+ levels in vitro (147).  Conversely, direct activation of SARM1 rapidly depletes 
intracellular NAD+ and is sufficient to induce axon degeneration (146, 147).  A key 
event that occurs after axotomy is the depletion of NMNAT2, which is sufficient to 
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trigger axon degeneration (148).  SARM1 appears to be the effector of NMNAT2-
depletion induced axon degeneration, as the degeneration trigged by NMNAT2 
depletion can be fully rescued by the co-deletion of SARM1 (149).  Downstream of 
SARM1, a MAP Kinase signaling pathway is activated to propagate the degenerative 
signal (150, 151). This cascade includes DLK (Dual Leucine Zipper Kinase), MEKK4, 
and MLK2 which leads to the activation of c-Jun-N-terminal kinases (JNKs) via MKK4 
and MKK7 (150).  Exactly how this signaling pathway induces axon degeneration is not 
fully understood, but Ca2+ signaling and calpain activation appear to be important for 
mediating late events in axon degeneration (152-154).  
 
Apoptosis (apoptosis-induced axon degeneration) 
Neuronal apoptosis, which results in the degeneration of both the soma and 
axons, occurs extensively during development (155). This process has been well 
studied in the developing peripheral nervous system where sympathetic and sensory 
neurons are acutely dependent on target-derived nerve growth factor (NGF) and if 
deprived of NGF will undergo apoptosis (156, 157).  This phenomenon can also be 
recapitulated in cell culture where dissociated sympathetic or sensory neurons, or 
ganglia explants, are maintained in the presence of NGF.  Elimination of NGF from the 
culture media, to deprive the entire neuron of NGF (often referred to as “global 
deprivation”), results in the apoptotic degeneration of both the soma and axons (156, 
158).   
Global deprivation of NGF initiates a well-defined apoptotic pathway that we 
briefly outline here.  NGF deprivation induces the dephosphorylation of its receptor, 
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Tropomysin receptor kinase A (TrkA), which leads to the activation of a DLK-mediated 
apoptotic signal.  DLK signaling activates downstream mediators (including JNKs, 
MAPKs, and GSK3β and leads to the transcriptional upregulation of proapoptotic BH3-
only family proteins (including Bim, Puma, Bmf, Hrk/DP5) by transcription factors such 
as c-Jun, NF-Y, and FOXOs (156, 159).  Recently, Puma was shown to be a key 
mediator of axon apoptosis.  Not only is Puma induced in the cell body after global NGF 
deprivation, but Puma deficiency markedly reduces axon apoptosis (159).  A major 
function of the BH3-only proteins such as Puma is to activate Bax, a pro-apoptotic 
member of the Bcl-2 family, which is required for neuronal apoptosis (156).  Some BH3-
only proteins directly interact with Bax to induce its conformation activation, while others 
inhibit anti-apoptotic proteins of the Bcl-2 protein family (Bcl-2, Bcl-w, Bcl-XL, Mcl-1) 
(160).  In particular, Bcl-w and Bcl-XL are known to be localized to axons where they 
are important for maintaining axonal survival (159, 161). 
Once Bax is activated, it translocates to mitochondria and inserts into the outer 
mitochondrial membrane, leading to the release of cytochrome c (cyt c) into the 
cytoplasm (162).  Released cyt c can then bind to Apaf-1 (Apoptotic protease activating 
factor 1) to induce a conformational change in Apaf-1 that results in the recruitment of 
and activation of procaspase-9 (Casp9).  Activated Casp9 functions to activate 
Caspase-3 (Casp3), and subsequently calpains, which together execute the 
degeneration of both soma and axons by targeting many cellular proteins for proteolysis 
(153).  Interestingly, while there are numerous mammalian caspases with diverse 
cellular functions, only Casp9 and Casp3 appear to be strictly required for global NGF-
deprivation induced neuronal apoptosis (163).  Lastly, X-linked Inhibitor of Apoptosis 
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Protein (XIAP) inhibits caspase activity in both soma and axons, but is degraded during 
global NGF deprivation (164, 165).  Consistent with this, XIAP-deficient neurons exhibit 
enhanced axon degradation when globally deprived of NGF (165). 
This apoptotic pathway activated upon global deprivation of NGF has been 
recognized to be important for the degeneration of both the cell bodies and axons.  
Indeed, deletion or depletion of the key effectors of this apoptotic program (e.g. DLK, 
JNKs, c-Jun, FOXO3a, Bax, Apaf-1, Casp9, Casp3) blocks the death of neurons in 
response to global NGF deprivation (156, 159, 163, 166).  Overall, these data suggest 
that in the context of global apoptotic stimulation, axonal degeneration is a 
consequence of the apoptotic program activated in the cell body. 
 
Axon pruning (pruning-induced axon degeneration) 
In addition to neuronal apoptosis, the nervous system undergoes substantial 
refinement by the pruning of axons and dendritic connections, which are selectively 
dismantled and rewired.  Pruning is critical not only for establishing specific and 
appropriate neuronal circuitry during development but also for neuronal plasticity in the 
adult nervous system (138, 167).  Precise spatial and temporal control of the 
degenerative machinery is important for pruning to ensure that only the targeted regions 
of the axons are degraded.  This spatial regulation is in contrast to apoptosis, where the 
entire neuron undergoes degeneration.   
Similarly to axon apoptosis, mechanistic insights into the axon pruning pathway 
have primarily come from studies in peripheral neurons (sensory and sympathetic) 
subjected to NGF deprivation.  An important distinction however is that while axonal 
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apoptosis is triggered by “global” deprivation of NGF (where neurons are completely 
deprived of NGF), axon pruning is observed in response to the selective deprivation of 
NGF from the axon while maintaining the neuronal cell body in NGF.  To study this 
pathway in vitro, neurons are cultured in compartmentalized chambers (e.g. Campenot 
(168) or microfluidic chambers (169)) where the cell bodies and the axons are 
maintained in different compartments, separated by a physical barrier, to keep them 
spatially and fluidically isolated.  Selective deprivation of NGF from only the axon 
compartment (known as “local” NGF deprivation), with cell bodies maintained in NGF, 
triggers the selective degeneration (pruning) of only the axons in the NGF-deprived 
axon compartment (168).  Although axon apoptosis and axon pruning are both induced 
by NGF deprivation, the distinction between global and local NGF deprivation is 
important as it defines the context, and thus, the specific pathway activated.  
While multiple factors are known to mediate axon pruning in vivo (138), the 
molecular pathway of axon pruning has been best studied in vitro in the context of local 
(axon-only) NGF deprivation. Amyloid Precursor Protein (APP) and Death Receptor 6 
(DR6) have been identified as key regulators of pruning in vivo (170, 171).  However, 
loss of either APP or DR6 was not protective against apoptosis (global NGF deprivation) 
in vitro (171), suggesting that APP and DR6 play a unique role in axon pruning but are 
dispensable for apoptosis.  During local NGF deprivation-mediated pruning, the loss of 
TrkA activity leads to the activation of DLK to induce a retrograde signal to the soma 
(159).  This signal is important, as DLK-deficient neurons are protected from axon 
pruning (159, 166).   DLK activation leads to the local phosphorylation of JNKs to 
propagate the pruning signal (166, 172).  Interestingly, inhibition of JNK (and also p38 
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MAPK) in only the axons, and not the cell bodies, is sufficient to protect against axon 
pruning, confirming their roles in transduction of the retrograde signal (172).  
Furthermore, GSK3 (both α and β)  is a potential JNK-regulated mediator of this 
retrograde signal as inhibition of GSK3 activity in the soma, but not the axons, protects 
against axon pruning (172).  While GSK3 could be activated locally in axons, its kinase 
activity may be required only in the soma where its substrates important for pruning 
could be spatially localized.  c-Jun has been identified as another soma-dependent 
transcriptional regulator that is activated during pruning (166, 173).  Whether c-Jun is 
required for axon pruning is undetermined however, as previous results examined the 
requirement of c-Jun in the context of axon apoptosis (global NGF deprivation) (159, 
166).    
Recently, the BH3-only protein Puma was identified as an essential mediator for 
axon pruning where its deficiency protects axons against local NGF deprivation (159).    
As Bax is also required for axon pruning (170, 174, 175), the role of Puma is likely to 
directly activate Bax.  Consistent with Bax activation, cyt c is released from 
mitochondria in axons undergoing pruning (174), but whether cyt c is required for 
pruning is not known.  This is particularly relevant as cyt c is known to activate Casp9 
via Apaf-1 on the apoptosome.  However, Apaf-1 is not required for axon pruning (174).  
While Apaf-1-deficient neurons are protected from undergoing apoptosis after global 
NGF deprivation (159, 163), they still undergo pruning after local NGF deprivation (174).  
Interestingly, despite not requiring Apaf-1, pruning requires both Casp9 (174) and 
Casp3 (174, 176).  Thus, Casp9 appears to be activated via an Apaf-1-independent 
mechanism during pruning.  This is particularly relevant in post-developmental mature 
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neurons, which are known to shut down the apoptotic pathway by turning off Apaf-1 
expression (177), yet maintain plasticity and remain competent to undergo pruning 
(174).  This finding not only supports but highlights the Apaf-1-independent nature of the 
pruning pathway and illustrates how neurons are able to exert precise and differential 
control over the apoptosis and pruning pathways.  Additionally, pruning is dependent on 
Casp6, a caspase which is not essential for apoptosis (170, 174, 176).  However, 
exactly how caspases are activated during pruning, or even their precise order of 
activation, remains unknown.  As pruning allows for the selective degeneration only the 
targeted axon, without degeneration outside of that target region, it is likely that caspase 
activation during pruning is spatially restricted (178).  One such mediator that restricts 
caspase activity during pruning is XIAP (dIAP in Drosophila) (174, 179), which could 
serve to spatially constrain degeneration to the desired region.  Indeed, XIAP-deficient 
neurons are unable to spatially restrict caspase activity and inappropriately accumulate 





1.10 Figures and Legends 
Figure 1.1: Mitochondrial morphology and macrostructural elements 
Mitochondria exist as double membraned organelles with the outer mitochondrial 
membrane existing a smooth surface enveloping the entire mitochondrion.  Within the 
outer mitochondrial membrane there exists the highly folded inner mitochondrial 
membrane, the highly folded regions of this membrane are known as the cristae.  
Between the outer and inner mitochondrial membrane lies the transmembrane space.  
Within the inner mitochondrial membrane is the mitochondrial matrix, where the 













Figure 1.2: The mammalian electron transport chain 
Depicted here is the flow of high energy electrion through the mitochondrial electron 
transport chain.  The transfer of electrons produces a lot of energy, which is used to 
pump protons out of the mitochondrial matrix across the IMM to the transmembrane 
space.  Complex I (I) takes in the initial event and passes the electron down the line 
with Complex II (II) to Complex (III).  Complex III then passes it to Complex IV (IV).  At 
each one of these steps, protons (H+) are pumped across the IMM to produce a 
mitochondrial membrane potential.  The membrane potential is harness by Complex 








Figure adapted from Ow WP et al, Nat. Rev. Cell Biol. (2008)  
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Figure 1.3: Illustration of human mtDNA 
Human mtDNA is a double-stranded, circularized 16,569 base pair genome that exists 
within the mitochondrial matrix.  The mtDNA encodes for 13 of the 90 essential protein 
components of the ETC , as well as encoding for all 22 of the mitochondria transfer 











Figure 1.4: The mammalian BER pathway. 
Illustrated here is short patch and long patch BER.  SP-BER is the predominant form of 
BER utilized by mitochondria.  Mediators of each step are indicated as appropriate.  For 










Figure 1.5: The mitochondrial microtubule motor complex 
Illustrated here is a mitochondrion in blue (top) attached the mitochondrial tether (Miro, 
along with Milton) which connects the mitochondria to microtubule motor proteins 











Figure 1.6: Graphical representation of the three contexts of axon degeneration 
 Axotomy-induced Wallerian degeneration is induced by severing an axon to induce the 
selective degeneration of the axon distal to the cut site.  Global NGF deprivation of 
young peripheral neurons induces axon apoptosis, where the entire neuron (both soma 
and axons) are degenerated.  Pruning is the selective degeneration of only the axon 
exposed to the pruning stimulus, leaving the cell body intact.  Pruning can be studied in 
compartmentalized (illustrated by the gray barrier) cultures where NGF can be 











Table 1.1: Shared and distinct components of the axon degeneration pathways 
Summary of the functional importance of select key proteins in mediating axon 
degeneration in the contexts of axotomy, apoptosis, and pruning. 
The degree of protection reported is represented as: +++ excellent or complete 
protection, ++ significant protection, + some protection, - no protection, ? not yet known.  





Table 1:  


















































































CHAPTER 2: CISPLATIN INDUCED MTDNA DAMAGE DIRECTLY INDUCES AXON 




DNA damage-induced cellular pathways have been extensively studied not only 
because the maintenance of genomic integrity is fundamentally important in all 
organisms, but also because chemotherapeutic drugs that induce DNA damage are 
frontline treatments for cancer therapy (180).  These DNA damaging events engage a 
number of downstream pathways depending on the degree of DNA damage.  While low 
levels of DNA damage can induce cell cycle arrest, senescence or differentiation, 
excessive DNA damage can lead to cell death via apoptosis (181).  This research has 
predominantly focused on the effects of DNA damage on the nucleus where the 
pathways engaged, including the nuclear DNA damage-induced apoptotic pathway, 
have been well characterized (182, 183).  It is becoming increasingly evident that 
exposure of cells to DNA damaging drugs induces not just nuclear DNA damage but 
also mitochondrial DNA (mtDNA) damage.  However, identifying the effects of mtDNA 
damage independent of nuclear DNA damage is challenging because of the difficulty in 
exposing only the mitochondria, and not nucleus, to DNA damaging drugs.   
One current model of examining the role of mtDNA damage is the “mutator” 
mouse model where the mitochondrial DNA polymerase-gamma (POLG) has a mutation 
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which causes POLG to have a defective proof-reading domain (184, 185).  These 
mutator mice slowly accumulate mtDNA damage from acquired errors incurred during 
mtDNA replication, incur increased oxidative stress, increased apoptosis, and exhibit an 
aging phenotype (185-187).  Another model of mtDNA damage utilizes mitochondrially-
expressed endonuclease restriction enzymes (188).  The expression of these mtDNA 
targeted endonucleases induces double-stranded breaks, which also resulted in an 
aging phenotype.  Both these mouse models underscore the importance of maintaining 
mtDNA fidelity and show that accumulated mtDNA mutations have the consequence of 
premature aging at the organismal level.  However, these mouse models are not easily 








Using microfluidic chambers to selectively induce mtDNA damage 
To selectively induce mtDNA damage without any nuclear damage, WE have 
taken advantage of the structure of primary neurons where the cell body and axons are 
spatially distinct.  While the cell body contains both nuclear and mitochondrial DNA, the 
axons do not have a nucleus and hence the only DNA in axons is mtDNA from the 
axonal mitochondria.  Importantly, we used primary neurons in a microfluidic-based 
compartmentalized chambers, which provide the ability to isolate the neuronal cell 
bodies both fluidically and spatially from the axons (Fig. 2.1A). These microfluidic 
chamber devices have been rigorously demonstrated to maintain fluidic separation 
between the soma and axon compartments (169, 189).  Importantly, exposure of only 
the axon chamber to DNA damaging agents is anticipated to induce selective damage 
to axonal mtDNA without affecting the nuclear DNA. 
Exposure of cells to the DNA damaging drugs such as cisplatin is known to 
induce damage to both nuclear and mitochondrial DNA (136).  Thus, we examined 
whether addition of cisplatin to only the axon chamber in our neuronal microfluidic 
model was capable of inducing mtDNA damage in the axonal mitochondria.  Using an 
established PCR amplification assay for detecting mtDNA damage, we found that 
cisplatin exposure induced substantial damage to mtDNA in the axon chamber (Fig. 
2.1B).  Importantly, we used γH2AX staining, a marker of nuclear DNA damage (190), 
to examine whether the addition of cisplatin to only the axon chamber induced any 
nuclear DNA damage.  γH2AX staining was virtually undetectable in the nucleus when 
cisplatin was added to only the axon chamber.  In contrast, robust γH2AX staining was 
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observed in the nucleus as expected, when cisplatin was added to both the soma and 
axon compartments (Fig 2.1C, D).  Together, these results show that addition of 
cisplatin to the axon chamber selectively induced mtDNA damage without inducing 
nuclear DNA damage.   
 
Axonal mtDNA damage is sufficient to trigger axon degeneration 
To determine if the induction of mtDNA damage in the absence of nuclear DNA 
damage was capable of inducing a degenerative or pathogenic state in cells, we added 
cisplatin to the axon compartment and monitored the axons over time.  Strikingly, we 
found that exposure of cisplatin to only the axon compartment induced robust 
degeneration of the exposed axons.  Consistent with the fact that addition of cisplatin in 
the axon compartment did not induce any DNA damage in the soma compartment, the 
axons and cell bodies in the soma compartment remained intact.  We assessed this 
degeneration by immunofluorescent staining of the axons with tubulin and quantifying 
the degree of degeneration using an established assay for quantifying axon 
degeneration (191).  In axons treated with cisplatin we observed greater than 90% axon 
degeneration while untreated axons remained healthy with minimal axon degeneration 
(Fig. 2.2A, B).   
To confirm that our finding that mtDNA damage induces axon degeneration was 
broadly observed with multiple DNA damage-inducing drugs, we examined the 
consequences of exposing axons to camptothecin or d4T.  While cisplatin induces DNA 
damage by the formation of a bulky covalent intrastrand crosslink, the Topoisomerase-I 
inhibitor camptothecin selectively binds the topoisomerase-I-DNA complex, resulting in 
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DNA strand breaks (192).  Also, the nucleoside analog d4T, also known as stavudine, 
has been shown to be capable of damaging mtDNA by binding and inhibiting the 
function of the mitochondrial DNA polymerase-γ (193).  Exposure of the axon 
compartment alone to camptothecin or d4T was also sufficient to induce axon 
degeneration as seen with cisplatin (Fig. 2.2C, D, E, F).  Thus, exposure of axonal 
mitochondria to multiple modalities of DNA damage was sufficient to induce axon 
degeneration. 
 
mtDNA damage-induced axon degeneration is not mediated by the pathways of 
apoptosis, axon pruning, or Wallerian degeneration 
The observation that exposure of axons only to DNA damage triggers axon 
degeneration provides an opportunity to examine the degenerative pathway activated 
selectively with mtDNA damage.  As discussed earlier, most previous studies have 
investigated the DNA damage-induced cellular pathways in a context where the entire 
cell (including both nucleus and mitochondria) is exposed to the DNA damaging drugs.  
In these contexts, DNA damage in neurons is known to induce cell degeneration via 
activation of the Bax- and Caspase-3 (Casp3) -dependent intrinsic apoptotic pathway 
(163, 194, 195).  Briefly, DNA damage induces Bax activation that results in the 
mitochondrial release of cytochrome c leading to the activation of Casp3 and cellular 
degeneration.  Neurons deficient in either Bax or Casp3 are protected from undergoing 
apoptosis when the entire cell is exposed to DNA damaging drugs (163, 194, 195). We 
examined whether this pathway was also important in mediating axon degeneration in 
response to selective mtDNA damage.  Specifically, we isolated neurons from Bax- or 
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Casp3-deficient mice and evaluated their ability to undergo axon degeneration in 
response to axonal exposure to cisplatin.  Surprisingly, neither the Bax- nor Casp3-
deficient neurons exhibited any protection against cisplatin-induced axon degeneration 
(Fig. 2.3A, B, C, D).  Thus, unlike the cellular degeneration induced by nuclear DNA 
damage, mtDNA damage induced axon degeneration does not appear to be mediated 
through the apoptotic pathway. 
In neurons, two additional pathways of axon degeneration have also been 
identified.  Axon degeneration in the context of axonal deprivation of nerve growth 
factor, activates the axon pruning pathway.  While axon pruning, like apoptosis, also 
involves activation of caspases, axon pruning is reliant on the activity of an additional 
caspase, Caspase-6 (Casp6).  To determine if any additional caspase-reliant pathways, 
such as axon pruning, are involved in mtDNA damage induced axon degeneration we 
used the pan-caspase inhibitor Q-VD-Oph hydrate (QVD).  We found that QVD was 
unable to protect axons in response to axonal cisplatin exposure (Fig. 2.3E, F).  These 
results indicate that neither the apoptotic nor the axon pruning pathways of programmed 
axon degeneration are required for mtDNA damage induced axon degeneration. 
Axon degeneration in the context of axotomy is mediated via the Wallerian 
degeneration pathway.  Wallerian degeneration is distinct from apoptosis or pruning and 
does not involve any caspase activation.  Instead, the underlying mechanism of axon 
degeneration here is a consequence of catastrophic metabolic failure induced by the 
activity of Sarm1.  As mtDNA damage would be expected to induce metabolic failure 
over time, we examined if axon degeneration observed in response to cisplatin occurred 
via Wallerian degeneration.  To examine this, axons of neurons isolated from Sarm1-
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deficient mice were exposed to cisplatin.  However, Sarm1-deficient axons did not 
appear to be protected and degenerated in response to cisplatin (Fig. 2.3G, H).  Thus, 
neither apoptosis not the two other well-recognized pathways of axon degeneration 
appear to be key mediators of mtDNA damage-induced axon degeneration. 
 
Inhibition of ROS protects against mtDNA damage induced axon degeneration 
As none of the identified pathways of axon degeneration appear to be required 
for the degeneration we observe in response to axon-only exposure to cisplatin, we 
decided to investigate alternative potential mechanisms of degeneration.  Cisplatin is 
widely used as a chemotherapeutic drug in various cancer therapies.  One of the well-
known complications of cisplatin therapy is peripheral neuropathy where peripheral 
axons degenerate to cause significant neurological discomfort in patients.  Interestingly, 
it has been reported that blocking the activity and generation of reactive oxygen species 
(ROS) using cell-permeable reduced glutathione (GSH) reduces the severity and 
incidence of peripheral neuropathies in patients treated with cisplatin (196-199).  The 
exact mechanism by which cisplatin induces peripheral neuropathy and how GSH may 
protect is unknown.  One possible mechanism of cisplatin-induced peripheral 
neuropathway is that axon degeneration is triggered in response to cisplatin-induced 
mtDNA damage in axons.   To determine whether the mtDNA damage-induced axon 
degeneration we observe is potentially mediated via the aberrant production of ROS in 
the neuronal axons, we examined whether inhibiting the activity of ROS using the cell-
permeable antioxidant GSH would confer protection.  Interestingly, we found that the 
addition of GSH to only the axons in cisplatin-exposed axons provided significant 
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protection to axons from degeneration, reducing the measured degeneration from 89% 
axon degeneration in the cisplatin alone exposed axons to less than 6% axon 





DNA damage-induced cellular pathway have been extensively studied not only 
because the maintenance of genomic integrity is fundamentally important in all 
organisms, but also because chemotherapeutic drugs that induce DNA damage are 
frontline treatments for cancer therapy (180).  DNA damage induces repair pathways 
that can either result in cell survival, or if the extent of DNA damage is excessive, can 
trigger cell death (in certain contexts, DNA damage can also induce senescence or 
differentiation)(181).  Justifiably, this research has predominantly focused on the effects 
of DNA damage on the nucleus where the nuclear DNA repair mechanisms or the 
nuclear DNA damage-induced apoptotic pathways have been well characterized (182, 
183).   
In contrast, our knowledge of the cellular pathways activated with mtDNAdamage 
is still limited.  An important endogenous source of mtDNA damage are the reactive 
oxygen species (ROS), that are produced as a byproduct of mitochondrial oxidative 
phosphorylation (200).  Spontaneous errors in the mtDNA replication machinery also 
contributes to mutations in mtDNA, which are known to accumulate with aging (85).  
Additionally, many exogenous agents such as ionizing radiation, environmental toxins, 
and chemotherapeutic drugs can also induce mtDNA damage.  Most of our current 
knowledge about the cellular pathways activated with mtDNA damage has been 
focused on mtDNA repair mechanisms.  For example, the primary mtDNA repair 
pathway is BER, although other repair mechanisms engaged include single strand and 
mismatch repair (45, 57, 85).  Notably, mitochondria seem to lack the NER pathway, 
which is typically used to repair insults such as bulky adducts or cisplatin-induced 
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intrastrand crosslinks (45, 57, 85).  As such, chemotherapy with cisplatin is known to 
induce substantial mtDNA damage, which is believed to not be repairable by the 
mitochondrial DNA repair machinery (201, 202). 
Unlike irreparable nuclear DNA damage that actives a p53-dependent, apoptotic 
cell death program, less is known about the exact consequences of having irreparable 
mtDNA damage in cells.  The main reason for this is that it is experimentally challenging 
to separate clearly the effects of nuclear versus mitochondrial DNA damage in cells.  
Other than the few notable exceptions highlighted below, most studies the have 
examined the molecular consequences of DNA damage in cells are in the context 
where the entire cell is exposed to the DNA damaging agent.  In those situations, both 
nuclear and mitochondrial DNA are damaged, and the cellular outcome observed could 
be a combined effect of both nuclear and mitochondrial DNA damage pathways.  Thus, 
to clearly define the cellular consequences mtDNA damage, there is a need to develop 
models where these chemotherapeutic drugs could selectively induce mtDNA damage 
without simultaneously also inducing nuclear DNA damage. 
The best-studied model is the “mutator” mice, which carry a knock-in mutation in 
the exonuclease domain of the mitochondrial DNA polymerase, POLG, that renders the 
exonuclease domain defective.  As this mutant POLG lacks its proof-reading activity, 
the mutator mice gradually accumulate mtDNA mutations and exhibit an aging 
phenotype (184, 185).  An increase in oxidative stress and apoptosis is observed in 
these mice but the exact mechanism responsible for the aging phenotype is not known 
(185-187).  Interestingly, the aging phenotype of these mice was recently shown to be 
rescued by physical exercise in a p53-dependent manner (203, 204).  While the function 
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of p53 in the repair of nuclear DNA damage is well established (182), several reports 
show that p53 can also interact with mtDNA, enhance the fidelity of mtDNA replication, 
and maintain mtDNA genomic stability (205-208).  Thus, mitochondrial homeostasis 
may not be efficiently restored by exercise in the absence of p53 in the mutator mice.    
Another mouse model of mtDNA damage is one where mtDNA double-stranded 
breaks could be induced by the expression of a mitochondrially-targeted restriction 
endonuclease (Pst1) (209, 210).  Even a transient induction of mtDNA double-stranded 
breaks is sufficient to induce an aging phenotype (211, 212).  These mice exhibited an 
increase in the nuclear induction of p53 (and p21), but the aging phenotype could not be 
rescued with the deletion of p53 (or p21) (212).   
Both these mouse models underscore the importance of maintaining mtDNA 
fidelity and show that accumulated mtDNA mutations have the consequence of 
premature aging at the organismal levels.  However, these mouse models are not an 
easily tractable model to identify the precise molecular pathways directly activated with 
mtDNA damage.  A few studies have induced mtDNA damage in cell lines.  Depletion of 
the exonuclease EXOG, which resulted in persistent single stranded brakes in mtDNA 
(but not nuclear DNA), induced cell death with apoptotic characteristics, but the 
molecular components of the cell death pathway were not examined (188).  
Interestingly, the Kelley group has recently developed mitochondrially-targeted 
doxorubicin (213) and mitochondrially-targeted cisplatin (214) and find that addition of 
these to cancer cell lines induces cell death; the molecular mechanism of cell death was 
not examined in these studies.   
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Our model system of utilizing microfluidic chamber devices provides for the 
spatial and fluidic isolation of the neuronal cells bodies from the nucleus.  This system is 
ideal for examining the effects of direct exposure of only the mitochondria, and not the 
nucleus, to DNA damaging drugs.  Our data show that the axonal mitochondria exposed 
to cisplatin in our microfluidic devices incur mtDNA damage while the nucleus of the 
same cells remain undamaged.  Our finding that cisplatin exposure to axons alone 
leads to significant axon degeneration while the untreated axons and nucleus remain 
intact is striking because it has not been shown before that DNA damage directed 
towards the mitochondria is capable of inducing degeneration without negative 
consequences to the nucleus.  These data suggest that mtDNA damage is capable of 
directly leading to the downstream degeneration of the affected cellular material nearby 
the damaged mitochondria.  It is notable that mitochondria completely lack the NER 
pathway for repairing more bulky adducts, among other types of mtDNA damage .  As 
mitochondria lack key DNA repair pathways that are utilized in the nucleus for nuclear 
DNA maintenance and repair, it is likely that the mtDNA may be more susceptible to 
damage in response to certain DNA damage insults.  Importantly, cisplatin intrastrand 
crosslinks that require the NER pathway, which is deficient in mitochondria, to be 
repaired (45, 81, 82).  Our findings that both the topoisomerase I inhibitor camptothecin 
and the nucleoside analog d4T are capable of also inducing axon degeneration when 
exposed to axons alone suggests that the degeneration we observe is not specific to 
cisplatin induced mtDNA damage.  Camptothecin and d4T induce DNA damage events 
through completely different mechanisms (likely through induction od double-stranded 
breaks), indicating that this is a conserved response to mtDNA damage.   
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There are a number of known pathways which can induce programmed cellular 
degeneration, but the three  pathways that have been best studied in the context of 
axon degeneration are axon apoptosis, axon pruning, and Wallerian degeneration.  
Axon apoptosis and axon pruning share a number of the same mechanistic components 
including the requirement for Casp3, Bax, and caspase activity, although the two differ 
slightly (axon apoptosis requires Apaf-1 and not Caspase-6 while axon pruning requires 
Caspase-6 but not Apaf-1).  As both axon apoptosis and axon pruning require Bax, 
which is known to permeabilize the mitochondrial membrane and induce energetic 
failure, it was attractive to consider that these pathways may play a role in mtDNA 
damage induced axon degenerations.  Our results show that Casp3-decifienct or Bax-
deficient neurons, or caspase inhibitor-treated neurons were incapable of significantly 
inhibiting axon degeneration in response to cisplatin-induced mtDNA damage.  These 
data show that the axon apoptosis and axon pruning pathways of programmed axon 
degeneration do not seem to be the key essential degeneration pathways activated with 
axonal mtDNA damage.  The third axon degeneration pathway that is well studied is the 
Wallerian degeneration pathway, which relies upon the key mediator Sarm1 to execute 
degeneration.  One of the apparent roles of Sarm1 is to induce energetic failure by 
depletion of key metabolic intermediates and thus was potentially interesting in the 
context of mitochondrial damage.  However, our findings with the Sarm1-deficient mice 
indicate that Sarm1 and the Wallerian degeneration pathways are also not essential 
mediators of cisplatin-induced axon degeneration.   
Interestingly, despite none of the known axon degeneration pathways being 
involved we were surprised to find that the addition of the antioxidant glutathione 
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appeared to robustly protect the axons from undergoing axon degeneration.  These 
data point to the involvement of ROS in the axon degeneration induced by cisplatin.  
The involvement of ROS in response to mtDNA damage is not surprising, as mtDNA 
damage in various other model systems has been shown to induce oxidative stress 
(105, 106).  However, the ability of an antioxidant to robustly inhibit the degeneration, 
that was not prevented by the inhibition of key degenerative pathways, is interesting.  In 
patients, it has been previously reported that the addition of glutathione was able to 
reduce some of the negative side-effects of cisplatin therapy.  Our data suggest that 
glutathione addition appear to prevent the degeneration that is induced in response to 
mtDNA damage.   
These findings are interesting because they could suggest new potential 
avenues of chemotherapeutic treatment therapies which could be designed to minimize 
CIPN.  However, we also find it important to note that if one of the ways that DNA 
damaging therapies is working to kill cancer cells is via damaging mtDNA then the 
addition of glutathione might actually serve to protect cancer cells from the 
chemotherapeutic regime itself.  Because little is understood about the exact 
contributions of mtDNA damage versus nuclear DNA damage in the outcomes of global 
cellular exposure we believe that additional study should be undertaken to further 
expand our knowledge on these roles.  These findings indicate that the currently well-
identified pathways of axon degeneration do not appear to be involved in the axon 
degeneration observed in response to cisplatin-mediated mtDNA damage.  There are a 
number of potential explanations for this observations, ranging from the involvement of 
a less-appreciated pathway for axon degeneration or the implication of an unidentified 
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pathway.  One interesting observation is that while the model system was in neurons 
and our findings were based on axon degeneration the consequences of mtDNA 
damage might be a more broadly applicable effect.  We examined the known pathways 
of axon degeneration because those were the most rational pursuits within our system, 
but the outcomes of mtDNA damage may trigger and engages a more basal pathway 
that is maintained by all cell types.  As mtDNA damage is a universal problem for all 
cells, it may stand to reason that the pathways engaged may too be universal.  The 
cellular pathways engaged directly by mtDNA damage remain poorly understood and 
future research seeking to differentiate the contributions of mtDNA versus nuclear DNA 
damage to cellular outcomes will be valuable in expanding our knowledge on how 




2.4 Materials and Methods 
Primary sympathetic neuronal cultures 
Primary sympathetic neurons were cultured as previously described (164).  
Briefly, sympathetic neurons were dissected from the superior cervical ganglia (SCG) of 
postnatal day (P) 0-2 CD1 mice.  Cells were plated directly into the microfluidic chamber 
device (described below) at a plating density of 10,000 cells per chamber and 
maintained for 5 days in vitro (DIV) in media containing NGF (AM50).  Mice deficient for 
Bax, Casp3, Casp6, and Sarm1 are all from C57BL/6 backgrounds and wildtype 
littermates served as controls.  
 
Fabrication and use of microfluidic devices  
Microfluidic device master molds were generated using standard 
photolithographical procedures.  Negative photoresist (MicroChem Corp, KMPR 1010) 
was utilized to pattern the chamber and microfluidic grooves.  The microfluidic grooves 
were etched at 3 μm deep grooves with a groove width of 10 μm with each groove 
being spaced 40 μm apart into a standard silicon wafer (Silicon Question International).  
The raw silicon surrounding the groove patterns was etched approximately 3 μm into 
the silicon wafer using deep reactive ion etching (Alcatel AMS 100 Deep Reactive Ion 
Etcher) using a low-roughness Bosch process.  The groove photoresist layer was then 
removed using 2800 W oxygen plasma.  The axon and soma compartments (750 μm 
long, 100 μm deep, 100 μm wide for each side) were added on either side of the etched 
grooves by addition of a negative photoresist layer of SU-8 (MicroChem Corp) followed 
by standard photolithographic procedure recommended by the manufacturer.  To 
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generate microfluidic devices, Sylgard 184 PDMS (Dow Corning) was prepared 
according to manufacturer protocol and  poured into the mold form.  The liquid mold 
was placed under vacuum to remove air bubbles from the PDMS for 30m then placed 
into a 65⁰C oven to cure overnight.  After curing, individual PDMS chambers were cut 
out and trimmed then soaked ddH2O overnight, sterilized in 70% EtOH, allowed to dry, 
then mounted onto cleaned glass coverslips coated overnight  in 40 µg/ml poly-D-lysine 
(Sigma, P7886) and 0.1 µg/mL mouse laminin (Invitrogen, 23017-015).   
 
Culture and treatment of primary neurons in microfluidic chambers 
Neurons were plated in microfluidic chambers as described previously (169) and 
maintained in AM50 until 5 DIV (or 28 DIV for mature experiments).  To treat cells with 
Global (both axon and soma chambers) drug treatment, both the axon and soma 
compartment are washed three times with AM50 media containing drug.  To treat cells 
with Local (axon chamber only) drug treatment, only the axon compartment is washed 
with AM50 containing drug while the soma compartment is maintained in untreated 
AM50 media.  A 30 μL volume differential was established between the soma and axon 
compartments and was reestablished every 12-20 hours to maintain fluidic isolation of 
the two compartments (169).  For drug treatments, compounds were added to AM50 
media at the following concentrations: 20 μM cisplatin (Sigma, P4394), 20 μM 
camptothecin (Tocris, #1100), 50μM d4T (Sigma, D1413), 25 µM QVD-OPh (SM 
Biochemicals, SMPH001).  For experiments using NGF deprivation as a positive control 
for apoptosis, cultures were rinsed three times in media lacking serum (AM0) and then 
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maintained in NGF-deficient media containing a neutralizing antibody to NGF.   All 
experiments were performed in triplicate. 
 
Axon Degeneration Quantification 
Degeneration of axons was quantified from immunofluorescent images stained 
for tubulin taken in the microfluidic devices.  The images are analyzed in ImageJ using a 




Immunofluorescence staining was carried out as previously described (174).  
Briefly, the two compartments are stained by added solutions to the top chamber 
reservoirs and allowing solutions to flow through into the chamber areas.  The following 
primary antibodies were used for staining: tubulin (Sigma, T9026), Tom20 (Santa Cruz, 
sc-11415), phospho-H2AX (Cell Signaling, 9718S).   Nuclei were labeled with Hoechst 
33258 (ThermoFisher, H3569). 
 
Image acquisition and processing 
Images were acquired on a DMIRE2 inverted fluorescent microscope (Leica) 
using an ORCA-ER B/W CCD camera (Hamamatsu) through Metamorph software 
(Molecular Devices, version 7.6).   
 
mtDNA damage analysis 
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mtDNA was acquired by collecting axon-only mtDNA from the axon compartment 
of treated and untreated axons using a DNeasy Blood & Tissue kit (Qiagen, 69504).  
The mtDNA was then amplified using primers specific to short (117bp) and long (10kb) 
amplicons of murine mtDNA as previously described (215, 216).  The 117bp short 
region used the following for amplification:  forward primer:  5′-CCC AGC TAC TAC CAT 
CAT TCA AGT-3′, reverse primer:  5′-GAT GGT TTG GGA GAT TGG TTG ATG T-3′.  
The 10kb long region used the following for amplification: forward primer: 5′-GCC AGC 
CTG ACC CAT AGC CAT AAT AT-3′, reverse primer:  5′-GAG AGA TTT TAT GGG 
TGT AAT GCG G-3′.  PCR was done using Platinum Blue TAQ (Invitrogen, 12580015) 
conditions for amplification were followed as previously described (216). The amplified 
mtDNA products were measured using a Picogreen DNA amplification assay as 
previously described using a Thermo Fluoroskan Ascent FL fluorescent plate reader 
(215).  Resulting values of the short and long mtDNA amplification fragments were then 
ratiometrically compared as previously reported to quantify the amount of mtDNA 




2.5 Figures and Legends 
Figure 2.1: Cisplatin addition to only the axons in compartmentalized cultures 
induces axonal mtDNA damage without damaging nuclear DNA 
(A) Illustration of the microfluidic chambers where neurons are placed in the soma 
compartment and allowed to extend their axons into the axon compartment through the 
microgrooves. (B) Neurons in microfluidic chambers were either left untreated (UNT) or 
treated with cisplatin to the axon chamber (Cis; axon only).  Shown is quantification of 
mtDNA damage represented as % undamaged mtDNA in axonal mitochondria as 
compared to untreated controls (n=3).  (C) Neurons in microfluidic chambers were left 
untreated (UNT) or treated with cisplatin to only the axon chamber (Axon only) or 
treated with cisplatin to both the compartments (Axon and Soma).  Shown are images of 
the neuronal soma stained with antibodies to pH2AX (Top panels).  Bottom panels show 
same images of nuclei stained with DAPI.  While pH2AX foci in the nucleus are 
observed in globally treated neurons (cisplatin added to both axon and soma 
compartments), no pH2AX foci are visible upon cisplatin exposure to the axon-only 
compartment.  (D) Quantification of pH2AX staining (n=3).  All experiments were 













Figure 2.2: mtDNA damage induced by cisplatin and other DNA damaging drugs 
in axons is sufficient to induce axon-specific degeneration. 
(A) Neurons in microfluidic chambers were left untreated (UNT; Left panels) or treated 
with cisplatin to only the axon chamber (Local Cis, 20 μM; Right panels).  Images of 
neurons stained with tubulin are shown at 120 hrs after treatment.  (B) Quantification of 
cisplatin induced axon degeneration (n=3) from (A).  (C) Neurons were treated in 
microfluidic chambers as in (A) with the nucleoside analog d4T (50 μM) for 120 hours 
and stained for tubulin.  (D) Quantification of the d4T induced axon degeneration 
induced axon degeneration (n=3) from (C).  (E) Neurons were treated in microfluidic 
chambers as in (A) with the topoisomerase inhibitor camptothecin (20 μM) for 120 hours 
and stained for tubulin.  (F) Quantification of the camptothecin induced axon 














Figure 2.3: Cisplatin-induced axon degeneration is mediated by the known 
pathways of axon degeneration. 
(A) Neurons were isolated from Bax-deficient mice in microfluidic chambers and treated 
with cisplatin applied only to the axon chamber (Local Cis; 20 μM) for 120 hours and 
stained for tubulin.  (B) Quantification of cisplatin induced axon degeneration (n=3) from 
(A).  (C) Neurons were isolated from Casp3-deficient mice in microfluidic chambers and 
treated with cisplatin applied only to the axon chamber (Local Cis; 20 μM) for 120 hours 
and stained for tubulin.  (D) Quantification of cisplatin induced axon degeneration (n=3) 
from (C).  (E) Neurons cultured in microfluidic chambers were treated with cisplatin 
applied only to the axon chamber in the absence (Local Cis; 20 μM) or presence of 
QVD (Local Cis+QVD; 20 μM) for 120 hours and stained for tubulin.  (F) Quantification 
of cisplatin induced axon degeneration (n=3) from (E).  (G) Neurons were isolated from 
Sarm1-deficient mice in microfluidic chambers and treated with cisplatin applied only to 
the axon chamber (Local Cis; 20 μM) for 120 hours and stained for tubulin.  (H) 









Figure 2.4: Addition of the cell-permeable antioxidant glutathione inhibits 
cisplatin-induce axon degeneration. 
(A) Neurons cultured in microfluidic chambers were treated with cisplatin applied only to 
the axon chamber in the absence (Local Cis; 20 μM) or presence of glutathione (Local 
Cis+GSH; 20 μM, 50 mM) for 120 hours and stained for tubulin.  (B) Quantification of 












CHAPTER 3: EXAMINATION OF THE CONSEQUENCES OF DIRECTED MTDNA 
DAMAGE ON MITOCHONDRIA 
 
3.1 Overview 
In Chapter 2, we investigated the outcomes to the neuronal axon induced by the 
exposure of cisplatin as well as examined the potential pathways engaged during 
degeneration.  Here, we examine the outcomes of mtDNA damage induced by cisplatin 
on mitochondria.   
DNA damage in the nucleus, where the nuclear DNA repair mechanisms or the 
nuclear DNA damage-induced apoptotic pathways are involved, are well characterized 
(182, 183).  In contrast, our knowledge of the cellular pathways activated with mtDNA 
damage is still limited.  Specifically, because of the challenges in inducing mtDNA 
damage acutely and directly.  The majority of cell culture models require the 
administration of damaging drugs to the entire cell, which prevents the examination of 
the consequence of mtDNA damage in the absence of nuclear DNA damage.  As a 
result, the exact cellular consequences for direct and acute damage to the mtDNA are 
unclear.   
MtDNA damage could lead to a variety of potential outcomes.  For example, 
mitochondria with damaged mtDNA may become dysfunctional, depolarize, and 
become targeted for degradation via Parkin-mediated mitophagy (217, 218).  This 
mitophagy is hallmarked by depolarization and aggregation of damaged mitochondria 
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that are to be eliminated.  A number of potential consequences exist for mitochondria 
that become depolarized.  If the damage is not severe, such compromised mitochondria 
may undergo repair in an attempt to regain membrane potential and functionality.  
Indeed, loss of membrane potential dislodges mitochondria from their microtubule 
motors while they decide whether to engage repair pathways or self-eliminate via 
mitophagy (120, 121).  MtDNA damage also can lead to the production of ROS.  An 
important form of mitochondrial ROS is superoxide, which is produced as a byproduct of 
mitochondrial oxidative phosphorylation, and is itself capable of damaging mtDNA (105, 
106, 200).  So while many potential outcomes exist for mtDNA damage, the exact 
consequences for directed mtDNA damage are not fully understood.   
In this chapter, we document several aspects of mitochondrial biology and how 
mitochondria respond to directed mtDNA damage.  These observations are ongoing 




3.2 Results and Discussion 
Axonal cisplatin exposure leads to mitochondrial aggregation prior to degeneration 
Having established that cisplatin is capable of inducing mtDNA damage and 
subsequent axon degeneration, we wanted to investigate the outcomes of mtDNA 
damage on mitochondria.  As mtDNA damage occurs rapidly in response to cisplatin 
exposure (within 24 hours), we decided to examine mitochondria prior to degeneration 
(which occurs by 120 hours after damage).  To determine whether cisplatin-induced 
mtDNA damage leads to mitochondrial deficits, we first examined if mitochondria 
underwent morphological changes in response to mtDNA damage.  We added cisplatin 
to the axon compartment of neurons cultured in microfluidic chamber devices and 
examined their morphology at 72 hours post-exposure (prior to axon degeneration).   
Cisplatin-exposed axonal mitochondria appeared to show swelling and aggregation in 
response to treatment (Fig. 3.1A).  When quantified, cisplatin exposure resulted in a 
significant reduction of numbers of individual mitochondria per unit area in the axon 
tracts (Fig. 3.1B).  Accompanying the decreased mitochondrial abundance, the average 
size of each individual mitochondria was determined.  We found that the average 
cisplatin-exposed mitochondria were more than twice the size of the average untreated 
mitochondria (Fig 3.1C).  Reduced mitochondrial abundance and apparent increased 
mitochondrial aggregation (or fusion) suggest that fusion might be involved in the 
mitochondrial response to cisplatin-induced mtDNA damage (110).  While mitochondrial 
fusion might be a viable mechanism to repair damage under physiological conditions, it 
relies on a large pool of healthy mitochondria to function as a repair pathway.  The 
majority of mitochondria must be healthy and functional in order for the fusion of a 
defective mitochondria to healthy ones to be strongly justified.  Under normal conditions, 
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where mitochondrial damage is likely restricted to a localized subset of the cellular 
mitochondria or to randomly distributed mitochondria, mitochondrial fusion is an 
adaptive repair approach.  However, in response to catastrophic mitochondrial damage, 
such as cisplatin exposure, it could be predicted that the fusion of two failing 
mitochondria together would not provide sufficient regenerative effects to restore them 
to full functionality. 
 
Cisplatin exposure causes mitochondria to lose the membrane potential 
An alternate explanation to mitochondrial fusion for the observation that axonal 
mitochondria appear to be aggregated together in response to cisplatin induced mtDNA 
damage is that the mitochondria may be significantly compromised and have lost their 
membrane potential.  A number of essential components of the mitochondrial ETC are 
encoded by the mtDNA.  Thus, damage to mtDNA could prevent those essential ETC 
components from being produced and eventually lead to the breakdown of ETC 
functionality and subsequent loss of membrane potential.  Upon loss of mitochondrial 
membrane potential, mitochondria would be then targeted for degradation by mitophagy 
(93).  When mitochondria undergo mitophagy they are enveloped in a large double 
membrane structure and fused together with lysosomes.  It is at this stage where they 
could appear to be large, highly fused structures when they are observed. 
   As mtDNA damage is known to induce deficits in the ability of mitochondria to 
effectively maintain their mitochondrial membrane potential, we examined if 
mitochondrial membrane potential was lost in response to cisplatin exposure (219).  As 
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we have previously determined that mtDNA damage occurs within 24 hours of exposure 
and we know that mitochondria appear to aggregate by 72 hours of exposure, we 
examined mitochondrial membrane potential at the intermediate time point of 48 hours.  
Indeed, we found that cisplatin-exposed mitochondrial lost their mitochondrial 
membrane potential as measured by the mitochondrial membrane potential indicating 
dye, TMRE (Fig 3.2A).  TMRE signal is lost in response to the direct exposure of 
mitochondria to cisplatin.  These data indicate that mitochondrial membrane potential is 
lost within 48 hours of exposure to cisplatin, prior to the observation of mitochondrial 
aggregation and fusion.   
 
Cisplatin-damaged mitochondria produce ROS in the form of superoxide 
Damage to the mtDNA is known to lead to additional dysfunction of aerobic 
respiration, metabolic failure, and the production of ROS.  Specifically, when mtDNA is 
damaged, ROS is produced in the form of the superoxide free radical from Complex I 
and Complex III of the mitochondrial ETC (100, 105, 106).  As we found that mtDNA 
damage is induced by cisplatin exposure along with loss of mitochondrial membrane 
potential, we determined if cisplatin exposure to mitochondria led to generation of ROS.  
Indeed, we found that cisplatin treatment to neuronal axons led to marked production of 
ROS in the exposed mitochondria, as measured by the superoxide free radical (Fig. 
3.3A).  The formation of superoxide here suggests that there is likely significant damage 
to the mitochondrial ETC in response to cisplatin exposure.  As superoxide is capable of 
damaging mtDNA by itself, these data suggest that the mtDNA damage induced by 
cisplatin can lead toward a feed-forward loop of further damage to the mtDNA by the 
consequent production of superoxide. 
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Cisplatin exposure leads to mitochondrial trafficking defects 
It is known that damage to mitochondria and loss of mitochondrial membrane 
potential leads to the cessation of microtubule trafficking along microtubules (120, 121).  
As we have found that cisplatin exposure to mitochondria leads to significant 
mitochondrial damage and the loss of the mitochondrial membrane potential, we 
investigated if cisplatin led to mitochondrial trafficking defects.  We used neurons 
isolated from the mitochondrially-targeted Dendra2 (mito-Dendra2) fluorescent reporter 
to conduct live-neuron imaging of mitochondrial movement in microfluidic chamber 
devices.  We took a number of live-image video captures of mitochondrial movement 
after axonal exposure to cisplatin and found that almost all mitochondrial movement 
was inhibited.  A representative image of one of these recordings is shown in Fig. 3.4A.  
Upon repeated analysis we were rarely able to observe any mitochondrial movement in 
cisplatin exposure axons, unlike the untreated axons which exhibited detectable 
mitochondrial movement patterns.   
Mitochondrial depolarization leads to the phosphorylation of the mitochondrial 
tether protein, Miro, to microtubule motors that induces the destabilization and 
degradation of Miro (120, 121).  Loss of the Miro tether to the microtubules motors 
prevents the trafficking of mitochondrial along the cytoskeleton.  CIPN, including 
cisplatin-induced CIPN, has been known to manifest itself in a phenotype where the 
axons of peripheral neurons “die-back” towards the cell body (130).   
As peripheral axons extend long beyond the cell body, they are increasingly 
exposed to the circulating fluids of the body, because axons have a high surface area to 
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cross-sectional ratio.  In the case of a patient being treated with a chemotherapeutic 
agent, those fluids will contain that agent.  Mitochondria that are physically present at 
the distal tip of a peripheral axon have been trafficked all the way from the cell body and 
out to the axon tip.  Those mitochondria along their journey to the axon tip, or back from 
the axon tip, may be exposed to significantly higher doses of a chemotherapeutic drug, 
such as cisplatin, than mitochondria more proximal to the cell body.  If those 
mitochondria were exposed to threshold doses of DNA-damaging drug on their 
anterograde journey then they may accumulate sufficient mtDNA damage to lead to the 
depolarization of their mitochondrial membrane and thus termination of movement along 
the axonal microtubules.  This means that the newly generated healthy mitochondria 
produced in the neuronal cell body could become damaged as they traffic out towards a 
damaged axon tip.  This progressive damage of the most distal mitochondria would 
manifest in a gradient of damage, where the most distal mitochondria to the cell body 
are the most damaged while the most proximal are the least affected.  As CIPN induced 
by cisplatin manifests in this way, it is possible that this may be a potential mechanism 
behind the “dying-back” disease manifestation.  The data we report here do not directly 
prove this hypothesis, but are consistent with it.   
 
Induction of mtDNA damage leads to increased mtDNA replication 
In this chapter we have examined the effects of cisplatin-induced mtDNA 
damage on mitochondria by primarily investigating the degenerative pathways involved.  
However, mitochondria likely exist in a more biologically dynamic state where they 
balance repair and survival against death and degeneration.  When an entire cell is 
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exposed to DNA damage, the cell makes a number of decisions about whether the 
damage is tolerable, whether the damage is repairable, or if it is so excessive that it 
should eliminate itself through apoptosis.  We wanted to determine if mitochondria 
attempted to alleviate damage to mtDNA by replicating themselves and expanding in 
response to mtDNA damage.  Here, we utilized a plasmid expressing a component of 
the mitochondrial POLG polymerase which, when expressed, is selectively localized to 
only the mitochondria undergoing actively mtDNA replication (220).  As a proof-of-
concept, we looked in HeLa  cells to find that cisplatin exposure appears to induce 
mtDNA replication as there is an increased number of mitochondria which costains with 
the POLG1 fluorescent reporter (Fig 3.5A).  These findings are very preliminary and in 
future experiments our plan is be to use this plasmid construct in primary neurons in the 
microfluidic culture system.  There, we would be to examine whether damage to axonal 
mitochondria induced increased mitochondrial proliferation in the exposed axons, the 





3.3 Materials and Methods 
Primary sympathetic neuronal cultures 
Primary sympathetic neurons were cultured as previously described (164).  
Briefly, sympathetic neurons were dissected from the superior cervical ganglia (SCG) of 
postnatal day (P) 0-2 CD1 mice.  Cells were plated directly into the microfluidic chamber 
device (described below) at a plating density of 10,000 cells per chamber and 
maintained for 5 days in vitro (DIV) in media containing NGF (AM50).  The mito-
Dendra2 fluorescent reporter mice were acquired from Jackson Labs.  
 
Fabrication and use of microfluidic devices  
Microfluidic device master molds were generated using standard 
photolithographical procedures.  Negative photoresist (MicroChem Corp, KMPR 1010) 
was utilized to pattern the chamber and microfluidic grooves.  The microfluidic grooves 
were etched at 3 μm deep grooves with a groove width of 10 μm with each groove 
being spaced 40 μm apart into a standard silicon wafer (Silicon Question International).  
The raw silicon surrounding the groove patterns was etched approximately 3 μm into 
the silicon wafer using deep reactive ion etching (Alcatel AMS 100 Deep Reactive Ion 
Etcher) using a low-roughness Bosch process.  The groove photoresist layer was then 
removed using 2800 W oxygen plasma.  The axon and soma compartments (750 μm 
long, 100 μm deep, 100 μm wide for each side) were added on either side of the etched 
grooves by addition of a negative photoresist layer of SU-8 (MicroChem Corp) followed 
by standard photolithographic procedure recommended by the manufacturer.  To 
generate microfluidic devices, Sylgard 184 PDMS (Dow Corning) was prepared 
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according to manufacturer protocol and  poured into the mold form.  The liquid mold 
was placed under vacuum to remove air bubbles from the PDMS for 30m then placed 
into a 65⁰C oven to cure overnight.  After curing, individual PDMS chambers were cut 
out and trimmed then soaked ddH2O overnight, sterilized in 70% EtOH, allowed to dry, 
then mounted onto cleaned glass coverslips coated overnight in 40 µg/ml poly-D-lysine 
(Sigma, P7886) and 0.1 µg/mL mouse laminin (Invitrogen, 23017-015).   
 
Culture and treatment of primary neurons in microfluidic chambers 
Neurons were plated in microfluidic chambers as described previously (169) and 
maintained in AM50 until 5 DIV (or 28 DIV for mature experiments).  To treat cells with 
Global (both axon and soma chambers) drug treatment, both the axon and soma 
compartment are washed three times with AM50 media containing drug.  To treat cells 
with Local (axon chamber only) drug treatment, only the axon compartment is washed 
with AM50 containing drug while the soma compartment is maintained in untreated 
AM50 media.  A 30 μL volume differential was established between the soma and axon 
compartments and was reestablished every 12-20 hours to maintain fluidic isolation of 
the two compartments (169).  For drug treatments, compounds were added to AM50 
media at the following concentrations: 20 μM cisplatin (Sigma, P4394).   
 
Immunofluorescence  
Immunofluorescence staining was carried out as previously described (174).  
Briefly, the two compartments are stained by added solutions to the top chamber 
reservoirs and allowing solutions to flow through into the chamber areas.  The following 
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primary antibodies were used for staining: tubulin (Sigma, T9026) Tom20 (Santa Cruz, 
sc-11415) Nuclei were labeled with Hoechst 33258 (ThermoFisher, H3569).  
Quantification of mitochondrial size and number was conducted using the ImageJ (NIH) 
particle count program. 
 
TMRE assay for mitochondrial membrane potential 
TMRE (Abcam) working stock solution was made up fresh from frozen stocks 
stocks immediately prior to use.  A working concentration of 50nM TMRE was made up 
in normal AM50 neuronal cell media.  Neuronal cell media was removed and replaced 
with the 50nM TMRE solution in AM50 and cells were replaced into the humidified 37oC 
incubator for 15 minutes.  After 15 minutes, cells were removed from the incubator and 
had the TMRE solution gently removed and replaced with PBS as per manufacturer’s 
instructions.  Cells were then imaged by fluorescent microscope. 
 
MitoSOX Red superoxide detection assay 
MitoSOX Red (Molecular Probes) was thawed and made up just prior to use 
using DMSO to make a 5mM stock which was then diluted to a working stock of 5 μM 
made up in neuronal AM50 media.  Neuronal culture media was removed and replaced 
with 5 μM MitoSOX Red working stock and the cells were incubated for 10 minutes in a 
humidified 37oC incubator.  After 10 minutes, the MitoSOX Red solution was removed, 
and the neurons were washed three times with prewarmed PBS and then immediately 




mtDNA replication assay 
The POLG fluorescent images were acquired by expression of the POLG1-GFP 
(also known as p55-GFP) plasmid, which was received as a kind gift from Dr. William C. 
Copeland (NIEHS) (220).  Experiments were done using HeLa cell lines (ATCC) which 
were cultured in DME media (Gibco) supplemented with 10% fetal bovine serum 
(Sigma) and 2mM glutamine (Gibco).  Adherent cells were passaged 1:10 using 0.25% 
trypsin (Gibco) when they were 70% confluent and treated with cisplatin (Sigma, P4394) 
at 70% confluence for 8 hours.  All cells were maintained at 37oC in humidified 
incubators containing 95% air and 5% CO2. 
 
Image acquisition and processing 
Images were acquired on a DMIRE2 inverted fluorescent microscope (Leica) 
using an ORCA-ER B/W CCD camera (Hamamatsu) through Metamorph software 
(Molecular Devices, version 7.6).  Live cell imaging videos were acquired through this 






3.4 Figures and Legends 
Figure 3.1: Axonal exposure to cisplatin induces mitochondrial aggregation in 
neuronal axons.  
(A) Cisplatin (20 μΜ) is added to the axons of neurons cultured in compartmentalized 
culture, where mitochondrial aggregation is observed. Arrows (red) indicate health 
mitochondria on the left untreated condition (NT), while arrows on the right point to 
aggregated mitochondria in the cisplatin exposed axons (Cisplatin).  Neurons were 
exposed to cisplatin for 72 hours, then stained for the mitochondrial marker Tom20.  (B) 
Quantification of the total number of mitochondria per unit area in healthy axons 
(Untreated) are compared to the number of mitochondria in locally treated axons (Local 
cisplatin) of the experiments done in (A) (n=2).  (C) Quantification of the average size of 











Figure 3.2: Cisplatin induces depolarization of axonal mitochondria 
(A) Axons of neurons cultured in microfluidic chamber devices were exposed to vehicle 
(UNT) or to cisplatin (Cis, 20 μΜ) for 48 hours.  The axons were then probed with the 
mitochondrial membrane potential assay of TMRE retention.  Mitochondria which 
maintain their membrane potential retain the red TMRE dye, depolarized mitochondria 
are unable to retain TMRE and appear black.  Phase contrast images of axons are 











Figure 3.3: Cisplatin exposure induces the production of ROS 
(A) Axons of neurons cultured in microfluidic chamber devices were exposed to vehicle 
(UNT) or to cisplatin (Cis, 20 μΜ) for 48 hours.  The axons were then probed for the 
production of superoxide using MitoSOX Red.  Red staining indicates the production of 
superoxide reactive oxygen species.  Phase contrast images of axons are provided to 










Figure 3.4: Cisplatin exposure disruptions mitochondrial trafficking 
(A) Axons of neurons isolated from mito-Dendra2 mice were cultured in microfluidic 
chamber devices and exposed to vehicle (UNT) or to cisplatin (Cis, 20 μΜ) for 96 hours.  
Live cell video recordings were taking over 10 minute time periods of one frame 
acquired per 5 seconds.  Here, a mitochondria indicated by a red arrow in the untreated 
condition is show trafficking down an axon.  No mitochondria in the cisplatin-exposed 
axons were measured to be trafficked, and this lack of motion is noted by the marking of 












Figure 3.5: Cisplatin exposure induces the attempted replication of mtDNA in 
HeLa cells. 
(A) HeLa cells were transfect with the POLG1/p55-GFP plasmid of the POLG 
holoenzyme and were exposed to vehicle (UNT) or cisplatin (Cis; 10 μM) for 8 hours.  
Cells were then fixed and stained for Tom20 and DAPI, representative images are 












CHAPTER 4: DISCUSSION 
 
4.1 Summary of findings 
Cisplatin-induced mtDNA damage, in the absence of nuclear DNA damage, induces 
cellular degeneration 
Almost all cells rely upon healthy and functioning mitochondria for the 
maintenance of cellular survival and viability.  These mitochondria serve a number of 
key functions for cells, ranging from maintaining calcium ion buffering, fatty acid 
oxidation, Krebs cycle, and essential metabolic pathways (221).  Due to their critical 
importance, cells have developed a number of processes by which to check for 
mitochondrial health and ensure repair or elimination of defective mitochondria.  Indeed, 
defects in these programmed pathways of mitochondrial maintenance are implicated in 
a number of diseases, such as in the case of mitophagy defects and Parkinson’s 
disease (99).  One aspect of mitochondrial biology that remains unclear is what are the 
exact cellular and mitochondrial consequences of mtDNA damage.  The cellular 
consequences of DNA damage, to both to the nuclear and the mitochondrial DNA, has 
been investigated.  However, these studies rarely are able to selectively examine the 
pathways engaged directly in response to mtDNA damage, and in the absence of 
nuclear DNA damage.   
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In order to investigate the consequences of mtDNA damage alone, we utilized 
microfluidic chambers that allow for the spatial and fluidic isolation of the neuronal 
axons from cell bodies.  This system allowed us to expose only the axon−and not the 
cell body−to the DNA damaging agents and examine the outcome of inducing selective 
damage to mtDNA independent of any damage to the nuclear DNA.  All work unless 
indicated otherwise was done in the paradigm of drug addition to only the axons and not 
the cell bodies of neurons cultured in compartmentalized cultures.  The main findings of 
this work are summarized below: 
1. Exposure of cisplatin to axonal mitochondria induced mtDNA damage. 
2. Nuclear DNA was not damaged when cisplatin was added to the axons alone 
(as indicated by pH2AX staining). 
3. Cisplatin exposure to axons was capable of inducing axonal degeneration, 
without loss of the cell body and proximal, unexposed, axons. 
4. To confirm that the mtDNA-induced degeneration was not specific to cisplatin, 
we confirmed that addition of the DNA damaging nucleoside analog d4T was 
also capable of inducing axon degeneration without loss of the cell body. 
5. Additionally, we confirmed the degeneration phenotype using a third DNA 
damaging agent, the topoisomerase I inhibitor camptothecin.  Exposure of 
camptothecin was also able to induce axon degeneration without loss of the 
cell body. 




7. The axon degeneration induced by cisplatin is not mediated by the axon 
pruning pathway. 
8. The axon degeneration induced by cisplatin is not mediated by the Wallerian 
degeneration pathway. 
9. The degeneration however is able to be inhibited by the addition of 
exogenous antioxidants in the form of cell-permeable glutathione. 
10.  Addition of cisplatin in axons appeared to induce mitochondrial aggregation, 
with reduced total numbers of mitochondria in axons while the average size of 
each individual mitochondria increased. 
11. The mitochondrial membrane potential appeared to be lost in response to 
mitochondrial cisplatin exposure, prior to axon degeneration. 
12. Mitochondria appear to produce ROS, in the form of the superoxide free 
radical, in response to mitochondrial cisplatin exposure. 
13. Mitochondrial trafficking appeared to be inhibited by cisplatin exposure, as 
determined by analysis of live cell imaging of axonal mitochondrial. 
14. Preliminary data in HeLa cells using a POLG1-GFP reporter indicated that 




4.2 Clinical relevance 
 As damage to mtDNA is something that can occur in any cell type throughout its 
existence, these findings have relevance to a number of potential clinical conditions and 
human health.  Here, we will discuss how these findings connect with human diseases 
and the potential meaning of these findings. 
 
Chemotherapy-induced peripheral neuropathies 
As previously discussed, one serious consequence of a number of 
chemotherapeutic regimes is CIPN.  CIPN is a progressive and persistent 
neurodegenerative disorder induced by chemotherapeutic treatment.  Up to 30-40% of 
patients undergoing chemotherapy are likely to encounter some form of CIPN during 
their treatment (125).  As CIPN can induce a variety of symptoms in the outer 
extremities (e.g. hands, feet) ranging from numbness, tingling, thermosensitivity, to 
extreme pain or loss of sensations (222).  These symptoms sometimes can cease after 
the end of treatment, but can often lead to enduring and irreversible neurological 
damage.   
The exact cause of CIPN is not exactly clear, but it appears that different drug 
classes may have different disease etiologies.  For example, the microtubule-disrupting 
chemotherapeutic taxanes (and vincristine) have been predicted to destabilize 
microtubules in neuronal axons (125).  Neurons are dependent upon functional 
microtubule networks for their function, survival, and maintenance.  Thus, it could be 
expected that disruption of these key networks potentially would lead to neurological 
deficits.  Other chemotherapeutic drugs such as cisplatin, carboplatin, and oxaliplatin 
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are all known to induce CIPN but have a less clear mechanism for inducing their 
neuropathic effects.  They have been shown to be able to induce some mtDNA 
damage, but the exact consequences of this damage has been unclear (222).   Some 
studies have shown that cisplatin, among others, was capable of increasing ROS 
production, damaging mtDNA, and disrupting mitochondrial function (222, 223).  It is 
important to note however that in these studies, cisplatin was exposed to the entire 
animal or to the entire cell.  As global exposure to DNA damage could induce a number 
of consequences, this experimental design makes it challenging to determine if these 
outcomes are induced by a number of potential causes including neuronal nuclear DNA 
damage, damage to supportive Schwann cells, induced by demyelination, and damage 
to mtDNA.   
In our studies, we found that unmodified cisplatin was able to directly induce 
mtDNA damage in primary peripheral neuronal axons, without any detectable damage 
to the nuclear DNA.  Additionally, as exposure of axonal alone to cisplatin was capable 
of inducing axon degeneration in this context these data suggest that the dying-back 
degeneration observed in CIPN might be a direct consequence of mtDNA damage.  Our 
findings that other DNA damage drugs were able to recapitulate our findings with 
cisplatin additionally supports the concept that sufficient mtDNA damage can lead to the 
degeneration of axons in CIPN.  However, we were not able to identify any of the known 
pathways of axon degeneration (apoptosis, axon pruning, and Wallerian degeneration) 
as being involved in this degeneration.  While inhibition of ROS did protect axons from 
undergoing cisplatin-induced axon degeneration it is not clear how this effect is 
mediated.  One potential option could be that mtDNA damage induces ROS production 
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which is the driver of degeneration and that inhibition of ROS is sufficient to protect 
against degeneration.  An alternate hypothesis is that the antioxidant addition actually 
prevents cisplatin from being able to induce mtDNA damage in the first place which 
would temper the initial damage as well as the ROS production.  Indeed, this remains 
an important clinical point as GSH has been given to patients undergoing cisplatin 
therapy (198, 224).  These studies have found that the addition of GSH indeed reduce 
the incidence of CIPN in patients.  However, if the possibility exists that GSH prevents 
cisplatin from being able to properly function in its role as a chemotherapeutic agent for 
cancer therapy then these therapies should undergo additional review to ensure they do 
not change patient outcomes to the therapy.  There may be other potential strategies 
however that could be designed to selectively mitigate damage to neuronal 
mitochondrial or mitochondria in general, which could provide a more targeted 
mechanism to reduce CIPN incidence without effecting patient cancer therapy 
outcomes.   
 
Damage to mtDNA as a potential mechanism for the effects of chemotherapeutic drugs 
While we have primarily focused here on the effects of selective mtDNA damage, 
it is worth considering these data in a broader context.   We found that mtDNA damage 
was able to directly induce cellular degeneration of the neuronal axon when exposed to 
cisplatin.  This suggests that damaged mtDNA could play a role in the degeneration of 
all cells exposed to DNA damage.  Normal healthy cells are generally thought to engage 
p53-mediated apoptosis in response to significant DNA damaging insults.  However, 
cells that have defective DNA damage response pathways, such as cancer cells, may 
99 
 
not engage in those apoptotic pathways to self-eliminate.  Yet, we find that DNA 
damaging drugs are still generally effective against cancer cells.  One possibility is that 
in these cells, DNA damaging drugs are simultaneously inducing mtDNA damage 
alongside DNA damage.  That is not to say that the effects of DNA damage are 
inconsequential, but instead that there may be a synergistic effect in many DNA 
damaging chemotherapies between mtDNA damage with nuclear DNA damage.  Future 
studies should be conducted to analyze the relative contributions of mtDNA versus 
nuclear DNA damage and how each contributes to cellular degeneration when the 






4.3 Future directions 
Cisplatin and other DNA damaging drugs 
While our findings have yielded interesting results, there remains a number of 
important questions that need to be answered.  Cisplatin-induced CIPN and the axon 
degeneration associated with it remains a problem, but cisplatin has been implicated in 
other non-nucleoside binding events (75).  These non-DNA bind events have included a 
number of proteins which if bound by cisplatin could lead to direct negative 
consequences (225).  While these complications do not diminish the value and insight 
of our findings as it relates to cisplatin-induced CIPN, it does raise a flag of caution.  
That concern is why we confirmed our findings that both d4T and camptothecin were 
capable of inducing axonal degeneration when exposed to only the axons and axonal 
mitochondria.   
Cisplatin mediates its DNA damage by binding to DNA bases themselves, but 
other bases within a cell are capable of reacting with its active moiety to cause binding 
events.  Unlike cisplatin, d4T is an antiretroviral nucleoside analog which is capable of 
being incorporated into the mitochondrial DNA by the mitochondrial polymerase POLG 
and has be associated with peripheral neuropathies in patients undergoing therapy for 
HIV infection (129).  Once it is attempted to be incorporated into the mtDNA by POLG it 
leads to the stalling of POLG, which can lead to subsequent damage to the mtDNA 
(193).  Camptothecin on the other hand is a topoisomerase-I inhibitor and can induce 
double-stranded DNA breaks a s a consequence of topoisomerase stalling (192).  Thus, 
these two DNA damaging drugs induce mtDNA through a completely different 
mechanism of action than cisplatin and because they do not form direct covalent bonds 
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with cellular materials, they are less likely to exhibit potential off target effects like those 
observed in cisplatin exposure.   
Therefore, it is reasonable to use the DNA damaging drugs d4T and 
camptothecin to follow-up our findings with cisplatin in axonal mitochondria.  As there 
might be some concern that our findings could be restricted to being relevant only in 
cisplatin-induced CIPN or global cisplatin exposure, it makes sense to conduct 
mechanistic follow-up studies using drugs that more specifically damage mtDNA with 
less potential off target effects.  Our results that d4T and camptothecin are capable of 
inducing axon degeneration are promising and it would be interesting to examine of the 
axon degeneration induced by these drugs is mediated by the three pathways of axon 
degeneration we previously examined in the context of cisplatin.   
 
Mitochondrial depolarization and mitophagy 
In Chapter Three, we observed that mitochondria exposed to cisplatin appeared 
to aggregate, become depolarized, and cease trafficking along microtubules.  These 
data are not fully complete, and these data should be expanded upon to make these 
findings publishable.   
Our results also indicate that cisplatin-damaged mitochondria lose their 
membrane potential.  Mitochondria which lose their membrane potential are targeted for 
degradation by the mitophagy pathway.  One interesting question that remains 
unanswered is if the mitophagy pathway engaged in response to cisplatin-induced 
mtDNA damage is protective or damaging to the outcome of the exposure cell.  This is 
an interesting question because there are reasonable arguments for both sides.  For 
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example, if damaged mitochondria are suffering from failure to maintain the proper 
functionality of the mitochondrial ETC and are producing ROS then they are potentially 
threatening the viability of the cell.  If that ROS production remains unchecked then the 
ROS could further induce mtDNA damage as well as potentially damage other, 
previously undamaged, mitochondria and amplify the amount of damage experienced 
by the cell.  In that scenario, it makes sense that the cell would want to engage the 
mitophagy pathway rapidly to eliminate any compromised mitochondria before they can 
cause further damage to the cell.  
However, on the other hand, if the cellular mitochondria are exposed to a huge 
impulse of DNA damage which damages almost all of the mitochondria then more 
caution is beneficial.  If almost all the mitochondria of a cell become damaged and 
subsequently eliminated by mitophagy then it would leave the cell with severely 
diminished mitochondria and could lead to cellular failure due to mitochondrial loss.  In 
that case, giving mitochondria time to attempt to repair themselves and their mtDNA to 
reestablish a membrane potential and ward off mitophagy would lead to an increased 
number of saved mitochondria that would allow a cell to survive. 
We propose than examining the consequences of mtDNA damage in Parkin-
deficient neurons would provide insight into the role of mitophagy in the context of 
mtDNA damage.  Parkin-deficient neurons are unable to selectively target depolarized 
mitochondria for degradation and thus are deficient in their ability to undergo mitophagy.  
Thus, if mitophagy is a pro-survival pathway in the context of mtDNA damage we expect 
that Parkin-deficiency would lead to reduced axon degeneration.  If elimination of 
damaged mitochondria was a key role of mitophagy in mtDNA damage then we would 
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expect that Parkin-deficient neurons would undergo axon degeneration more quickly.  
Either of these possibilities is possible and either one provides an interested insight into 






4.4 Concluding remarks 
The work described here shows that cisplatin is directly capable of inducing 
mtDNA and axon degeneration.  While we found that this degeneration was not 
mediated by the known pathways of axon degeneration (apoptosis, axon pruning, and 
Wallerian degeneration), we did find that mtDNA damage induced axon degeneration 
was protected against by the inhibition of ROS by GSH.  These findings have 
implications in the current treatment of cisplatin-induced CIPN by patients and the 
viability of GSH supplementation.  In addition, these data shown that axonal mtDNA 
damage induced by cisplatin leads to a wide variety of mitochondrial deficits and 
compromised functionality.  These findings suggest that mtDNA damage may play an 
important role in the cellular response to global DNA damage, and provide a more 
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